

City Research Online

City, University of London Institutional Repository

Citation: Fan, Q., Pozarickij, A., Tan, N. Y. Q., Guo, X., Verhoeven, V. J. M., Vitart, V., Guggenheim, J. A., Miyake, M., Tideman, J. W. L., Khawaja, A. P., et al (2020). Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error. Communications Biology, 3(1), 133. doi: 10.1038/s42003-020-0802-y

This is the published version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: https://openaccess.city.ac.uk/id/eprint/24654/

Link to published version: https://doi.org/10.1038/s42003-020-0802-y

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online: http://openaccess.city.ac.uk/ publications@city.ac.uk/



ARTICLE

https://doi.org/10.1038/s42003-020-0802-y

OPEN



1

Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error

Qiao Fan et al.#

Corneal curvature, a highly heritable trait, is a key clinical endophenotype for myopia - a major cause of visual impairment and blindness in the world. Here we present a trans-ethnic meta-analysis of corneal curvature GWAS in 44,042 individuals of Caucasian and Asian with replication in 88,218 UK Biobank data. We identified 47 loci (of which 26 are novel), with population-specific signals as well as shared signals across ethnicities. Some identified variants showed precise scaling in corneal curvature and eye elongation (i.e. axial length) to maintain eyes in emmetropia (i.e. HDAC11/FBLN2 rs2630445, RBP3 rs11204213); others exhibited association with myopia with little pleiotropic effects on eye elongation. Implicated genes are involved in extracellular matrix organization, developmental process for body and eye, connective tissue cartilage and glycosylation protein activities. Our study provides insights into population-specific novel genes for corneal curvature, and their pleiotropic effect in regulating eye size or conferring susceptibility to myopia.

^{*}A full list of authors and their affiliations appears at the end of the paper.

efractive error is common worldwide and particularly so in Asia, where uncorrected refractive error is one of the major causes of visual impairment and blindness^{1,2}. In 2015, uncorrected refractive error caused moderate or severe visual impairment in 116 million people, and blindness in 7.4 million people—these figures are expected to rise to 128 million and 8.0 million, respectively, by 2020³. Thus there is a critical need to better understand the genetic basis of how different optical components may contribute to ammetropia, for which corneal curvature represents a main endophenotype.

Corneal curvature (CC) is a key clinical endophenotype for the refractive status of the eye. The corneal air-tissue interface provides approximately two-thirds of the eye's optical power⁴. Thus, changes in the CC significantly affect refractive error, such as myopia. A steeper CC was associated with a more negative/myopic refractive error. In the emmetropic eye, the refractive power of the eye's optical components (such as CC) must be appropriate to its axial length (AL). If the changes in CC, AL, or other ocular components such as lens thickness or anterior chamber depth are not aligned, refractive errors (myopia or hyperopia) are likely to occur.

Clinically, CC associates with ethnicity^{5,6}, age⁷, and anthropometric features (height and weight)⁷. Based on family and twin studies, CC is highly heritable, with 35-95% of inter-individual CC variation attributed to genetic factors^{8–12}. Previous genomewide association studies (GWASs) have been successful in identifying more than 160 loci associated with refractive error^{13–15}, and nine loci associated with AL16. Only four loci associated with CC have been previously reported from GWAS analyses: MTOR¹⁷, CMPK1¹⁸, and RBP3¹⁸ identified in Asians, and PDGFRA in both Asians¹⁷ and Europeans^{11,19}. A further 31 loci in European emmetropes, accounting for an additional 2.3% of variance in CC, have also been provisionally reported²⁰. Associated variants identified to date cannot fully explain the additive genetic variance of CC, and hence other genetic variants are likely to contribute to this endophenotype. The difference in the prevalence of myopia in various ethnic groups, particularly in Asia, also suggests that certain CC-associated alleles may be population-specific¹¹. Furthermore, the extent to which shared or distinct genetic loci contribute to variation in CC, AL, and spherical equivalent is uncertain.

Thus, we conducted the largest GWAS meta-analysis of CC to date, incorporating both European and Asian cohorts in a single analysis from the Consortium for Refractive Error and Myopia (CREAM) and validated our findings in the United Kingdom (UK) Biobank.

Results

Primary GWAS of corneal curvature. The CREAM discovery cohorts included 29,580 individuals with European ancestry from 18 studies, and 14,462 individuals with Asian ancestry from 10 studies. The demographics of these 44,042 participants are shown in Supplementary Table 1. GWAS analyses for CC were performed at the cohort level for all variants genotyped or imputed using the 1000 Genomes Project data as reference panels (Supplementary Table 2). The genomic control inflation factor ($\lambda_{\rm GC}$: 0.872–1.085) showed little evidence of inflation in test statistics at the study level.

We applied a uniform set of quality-control procedures to all cohort-level GWAS results in CREAM and meta-analysed up to 8.94 million variants (see Methods). For the discovery phase, we performed an inverse-variance-weighted meta-analysis on the European and Asian populations. The quantile-quantile plot for the trans-ethnic meta-analysis (λ_{GC} : 1.119; Supplementary Fig. 1) indicated moderate inflation, and genomic control-adjusted test statistics were generated. The inflation is partially due to polygenicity as the linkage disequilibrium (LD)-score regression intercepts were close to one²¹ (LD-score regression intercept of 1.045 in Europeans and 1.013 in Asians).

Figure 1 shows the Manhattan plot for the trans-ethnic meta-analysis for CC. We identified 41 loci at genome-wide significance $(P < 5.0 \times 10^{-8})$; Table 1; Supplementary Figs. 2–4). We performed replication analyses of these loci for CC in 88,218 participants with European ancestry from the UK Biobank. Thirty-seven (90.2%) of the 41 lead variants passed genome-wide significance in the UK Biobank data (Table 1). The signals of the two loci (*CMPK1/STIL*, *RBP3*) not reaching genome-wide significance in the replication phase were mainly driven by the CREAM Asian populations. In the combined CREAM and UK Biobank meta-analysis, the five most strongly associated loci were *RSPO1* (rs4074961; $P = 6.51 \times 10^{-100}$), *HUS1* (rs12702376; $P = 2.77 \times 10^{-86}$), *FGF9* (rs9506725; $P = 1.21 \times 10^{-78}$), *PDGFRA*




Fig. 1 Manhattan plot of trans-ethnic GWAS meta-analysis for corneal curvature. Both directly genotyped and imputed variants were meta-analysed for corneal curvature in 44,042 CREAM participants. The *y*-axis represents $-\log_{10}p$ values for association with corneal curvature, and the *x*-axis represents genomic position based on human genome build 37, highlighting newly identified loci (arrows in blue; Table 1), loci associated with axial length (labelled with nearest gene names), and loci associated with spherical equivalent (cross in green). The horizontal red line indicates the genome-wide significance level of $P < 5.0 \times 10^{-8}$. The horizontal blue line indicates the suggestive significance level of $P < 1.0 \times 10^{-5}$.

STAPP CHR POS GENE(S) MIVAR AVG GAR POH CAR POH CAR CA						CREAN	M-eur (<i>n</i> =	29,580)	CREAN	CREAM-asn (n =	= 14,462)	CREAM	CREAM ($n=44,042$)	ର		CK B	UK Biobank (n=88,218)	-88,218)	All combined	bined
11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 1118689784 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 11186897 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 1118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 118697 1	SNP	품	1	GENE(S)	A1/A2	EAF	9			β	b	β	٥	Het-I ²	het-P	Fred	β	d	Het-12	P
1 380902723 RNA 0.043 0.024 5.887 0.046 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0	rs3737611	_	11186897	MTOR	A/G		ı	2.08E-05		ı	6.73E-21	-0.041	l``	0.00	0.523	0.98	-0.041	1.30E-23	0.00	1.36E-46
4785397 ONE WRITCHING A/G 0.00 NA NA 0.21 0.033 38.2E-15 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003	rs4074961	.	38092723	RSP01	1/C			5.83E-22			4.10E-10	0.022		16.20	0.206	0.44	0.022	1.40E-73	0.00	6.51E-100
1 C586787 APP (176) 1/G (176) 0.018 (176) 5/1E-10 (136) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) 0.001 (176) <	rs60078183ª	-	47857307	CMPK1/STIL	A/G			Y V			3.82E-15	-0.037		0.00	0.694	0.00	-0.034	4.80E-01	0.00	4.47E-16
2 217619036 GRBPS/TIMP 1/C 0.116 0.016 1.05E-04 0.016 2 217619036 GRBPS/TIMP 1/C 0.10 0.016 1.05E-04 0.016 3 135390937 GRBPS/TIMP 1/C 0.10 0.013 1.17E-15 0.00 NA NA 0.013 3 1353390937 LOCAR A/T 0.10 1.18E-05 0.41 0.019 0.003 4 1305156 LOCAR A/T 0.21 0.011 1.28E-07 0.009 5.08E-03 0.001 4 18015156 LOCAR A/T 0.27 0.014 1.28E-07 0.019 2.0E-07 0.010 4 18015156 LOCAR A/T 0.23 0.016 1.48E-07 0.03 2.0E-0 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.014 0.019 0.019 0.014	rs945170	_	62867483	USP1	T/G			5.11E-12			2.91E-02	-0.014		27.74		0.26	-0.012	1.10E-19	0.00	2.64E-30
2 233390937 CHMONT/PRISSS A/G 0.049 5.27E-09 0.38 -0.013 2.9EE-04 -0.014 3 17213743 RNC3B/GHSR C/G 0.31 -0.015 1.7EE-09 0.38 -0.013 9.9EE-04 -0.014 3 17213743 RNC3B/GHSR C/G 0.31 -0.015 1.7EE-09 0.49 -0.003 5.08E-03 -0.013 4 18015156 LOOR A/G 0.21 -0.022 9.9GE-15 0.23 0.013 2.0EE-04 0.003 4 55094467 POGRRA A/G 0.21 -0.022 9.9GE-15 0.23 0.016 1.8EE-07 0.01 3.0EE-07 0.00 0.013 4.42E-05 0.00 4 7473151 A/G 0.27 0.015 1.7EE-07 0.01 1.1EE-02 0.013 5 170 0.01 1.7EE-07 0.01 1.7EE-07 0.01 1.7EE-07 0.01 1.7EE-07 0.01 1.7EE-07 0.01 1.7EE	rs1548942	7	217619036	IGFBP5/TNP1	T/C			5.62E-07	0.19	0.016	1.05E-04	0.016	•	0.00	0.757	0.15	0.021	6.40E-37	3.76	5.14E-50
3 13554886 HOACTIVEBLNI T/G 0.10 0.33 177E-15 0.0 NA NA 0.0 3 18254886 HOACTIVEBLNI T/G 0.31 -0.01 178E-05 0.41 0.003 508E-05 0.01 4 18005156 LCORL A/T 0.21 0.014 128E-07 0.8 0.014 202E-04 0.014 4 5509464 CAC 0.21 0.014 128E-07 0.8 0.014 202E-0 0.014 4 7347361 ADAMITSS A/G 0.27 0.014 128E-07 0.8 0.016 148E-09 0.03 2.0E-0 0.013 5 4373640 CAC 0.04 2.0E-0 0.01 2.0E-0 0.01 1.0E-0 0.01 6 13810450 CAC 0.04 0.02 1.0E-0 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02<	rs2245601	7	233390937	CHRND/RPSS56	A/G			5.27E-09		-0.013	2.95E-04	-0.014		0.00			-0.015	5.40E-38	0.00	1.29E-48
3 17237343 FNDC3B/GHSR Ç/G 0.31 -0.015 178E-08 0.49 -0.009 SOBE-03 -0.012 4 181836444 SOXZ ACTA 0.31 1.78E-05 0.41 0.003 8.88E-05 0.001 4 18013156 LOXA ACTA 0.21 -0.024 0.013 8.88E-05 0.001 1.88E-05 0.01 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014	rs2630445ª	m	13554886	HDAC11/FBLN1	T/G			1.17E-15			٧Z	0.030		0.00			0.031	8.80E-55	00.00	4.92E-67
3 187363446 SOXZ ACT/A 0.34 0.011 148E-05 0.41 0.012 0.014 0.012 0.014 0.012 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014	rs485554	m	172137343	FNDC3B/GHSR) () ()			178F-08			5.08F-03	-0.012		25.11			-0.012	1.60E-19	0.00	2.12E-27
4 18015556 LCORL A7T 0.27 0.014 1.28E-07 0.03 0.022 0.024 2.02E-04 0.003 4 55094467 PDGFRA A7G 0.27 0.014 1.28E-07 0.014 2.02E-04 0.003 4 128113424 RPII-1250181 A/G 0.27 0.012 1.28E-07 0.013 4.2EE-07 0.003 0.003 2.005-07 0.003 1.28E-07 0.001 1.5EE-02 0.003 5 64319640 CWCZYADAMTSS A/G 0.02 1.24EE-07 0.01 1.5EE-02 0.013 6 10028826 CMCCT A/G 0.07 0.02 2.24E-09 0.00 1.15E-02 0.013 6 113443139 UG CMCT A/G 0.07 0.02 2.24E-09 0.00 1.15E-02 0.013 6 113443139 UG CMCT A/G 0.07 0.02 2.26E-09 0.00 1.15E-02 0.013 6 11344	re10663094	· ~	181363464	2XOS	A/T/A			1.48F-05			8 88F-05	0.012	_	194		0.35	0.012	9 70F-23	000	1 27F-30
4 55094467 COCCAL A/G 0.27 0.024 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03	750000151) <	18015156	2005	(\ \ \ \ \			1.48E-03	- α - α - α		2.03E-03	20.0	174E-10	100	0.4.0	20.0	0.0	7.70E-23		1 10F-31
4 13028343 AVG 0.28 0.022 1.2012 0.022 2.022 0.023 0.023 0.022 2.022 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.024 0.023 0.	21000012	t <	500000	COVE POOLED A	- ()			1.20L-07			2.02L-04	10.0	7.745	20.00	2 5	0 0	0.0	2.70E-21	5 5	1 505 73
4 7434351 APAMMANA AVG 0.38 0.010 1.488-09 0.00 2.010-02 2.010 5 64319640 CWCZ7ADAMTSA AVG 0.03 1.488-09 0.01 1.15E-02 0.013 5 79306475 FHBSA AVG 0.03 2.48E-07 0.01 0.018 4.42E-05 0.01 5 1720088784 ADAMTSI9/CHSY3 1/C 0.02 0.028 2.49E-07 0.01 0.018 0.018 0.028 6 120088784 ADAMTSI9/CHSY3 1/C 0.02 0.012 3.34E-06 0.26 0.018 0.028 6 120088826 OFCT 1/C 0.04 0.011 131E-04 0.03 0.015 0.015 6 12008826 OFCT 1/C 0.04 0.013 1348-0 0.015 0.012 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.	12/12/00	4 •	10,410,41	rugrka 11111	ָט נ אַ אַ			9.90E-15	0.73	0.024	2.19E-10	-0.023	0.446-23	90.00	0.0	0.22	0.020	3.60E-43	4. 0	1.39E-73
4 128H3424 RPH-1250H8T A/G 0.27 0.013 2.88E-07 0.20 0.013 1.28E-07 0.010 1.15E-05 0.013 5 79360T5 THBS4 A/G 0.02 0.028 0.015 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 <t< td=""><td>rs/65/200</td><td>4 .</td><td>/34/3151</td><td>ADAMISS</td><td>۸/S</td><td></td><td></td><td>1.48E-09</td><td>0.37</td><td>0.008</td><td>2.20E-02</td><td>0.013</td><td>6.50E-10</td><td>0.00</td><td>0.8/3</td><td>0.39</td><td>0.014</td><td>3.70E-29</td><td>0.00</td><td>2.23E-38</td></t<>	rs/65/200	4 .	/34/3151	ADAMISS	۸/S			1.48E-09	0.37	0.008	2.20E-02	0.013	6.50E-10	0.00	0.8/3	0.39	0.014	3.70E-29	0.00	2.23E-38
5 64319640 CWCZ/ADAMTS6 T/C 0.40 0.014 2.48E-07 0.201 1.15E-02 0.013 5 79360175 THBSAZ A/G 0.08 0.028 1.49E-07 0.010 1.15E-02 0.013 6 129088784 ADAMTS19/CHSY3 T/G 0.08 -0.028 1.17E-10 0.05 -0.018 6.015 0.018 0.015 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 0.018 <td>rs6831679</td> <td>4</td> <td>128113424</td> <td>RP11-125018.1</td> <td>A/G</td> <td></td> <td></td> <td>2.80E-07</td> <td>0.40</td> <td>0.013</td> <td>4.42E-05</td> <td>0.013</td> <td>9.78E-11</td> <td>0.00</td> <td>0.808</td> <td></td> <td>0.008</td> <td>3.50E-10</td> <td>3.57</td> <td>1.14E-18</td>	rs6831679	4	128113424	RP11-125018.1	A/G			2.80E-07	0.40	0.013	4.42E-05	0.013	9.78E-11	0.00	0.808		0.008	3.50E-10	3.57	1.14E-18
5 79360175 7HBS4 A/G 0.028 1.17E-10 0.05 -0.018 6.68E-02 -0.028 6 122068782 APAM/TSI9/CHSY3 1/G 0.07 0.028 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 <	rs11740254	2	64319640	CWC27/ADAMTS6	1/C		0.014	2.48E-07	0.27	0.010	1.15E-02	0.013	1.55E-08	0.00	0.827		0.011	6.70E-21	0.00	4.96E-30
5 129088784 ADAMITSI9/CHSY3 T/G 0.07 0.028 2.49E-09 0.00 NA NA 0.003 6 10028826 OFCT A/T 0.28 -0.012 3.34E-06 0.015 2.42E-05 -0.013 6 113443139 UG T/C 0.24 0.011 1.91E-04 0.33 0.014 1.32E-05 0.013 6 138869568 NHSLI T/C 0.26 0.013 2.90E-07 0.58 -0.015 3.3E-05 0.013 7 24775053 HUSI T/C 0.03 2.90E-07 0.58 0.015 3.3E-05 0.013 9 129433929 LMXIB A/C 0.02 0.028 0.26 0.017 3.2E-08 0.017 4.2E-07 0.028 10 29024959 RNAT A/C 0.02 0.018 1.2E-10 0.01 4.2E-07 0.01 10 90024959 FRATI/FRATZ A/C 0.26 0.015 2.4E-10	rs13180294	2	79360175	THBS4	A/G			1.17E-10		-0.018	6.68E-02	-0.027	3.37E-11	0.00	0.479		-0.015	7.50E-14	6.85	2.46E-22
6 10028826 OFCCI A/T 0.28 -0.012 3.34E-06 0.26 -0.015 2.42E-05 -0.013 6 12064639 CASCIS T/C 0.24 0.014 2.11E-08 0.78 0.015 4.00E-03 0.013 6 138869568 NHSII T/C 0.20 0.011 1.91E-04 0.015 3.3E-06 0.014 0.013 7 47775053 HUSI T/C 0.84 -0.013 2.90E-07 0.58 -0.015 3.3E-06 -0.014 9 137433426 CULSAI T/C 0.84 -0.015 3.5E-18 0.01 1.3EE-08 -0.014 10 48388228 RBP3 T/C 0.42 -0.015 3.5E-18 0.01 1.29E-03 -0.013 10 49074959 RATJERATZ A/C 0.42 -0.015 3.5E-08 0.04 -0.015 3.5E-08 0.01 1.3EE-03 0.011 1.3EE-08 0.011 1.3EE-08 0.011 1.3EE-08	rs7708378 ^a	2	129088784	ADAMTS19/CHSY3	1/G			2.49E-09		ΥZ	ΥZ	0.028	2.49E-09	0.00	0.474		0.028	2.80E-34	0.00	5.51E-45
6 22064639 CASCIS T/C 0.44 0.014 2.11E-08 0.78 0.012 4.00E-03 0.013 6 13443139 U6 T/G 0.20 0.011 1.9FE-04 0.33 0.014 1.3ZE-05 0.013 7 47775053 HUS1 T/C 0.34 -0.028 -0.024 0.68F-03 -0.024 9 129433929 LMXIB A/G 0.02 0.024 0.27 0.02 1.2843822 9 129433929 LMXIB A/G 0.05 0.024 1.07 1.82E-08 -0.014 10 43838228 RBP3 T/C 0.04 -0.015 3.5E-08 0.071 1.82E-07 0.02 10 90024599 RNLS A/C 0.02 0.018 1.26E-10 0.80 -0.013 1.28E-04 -0.013 10 90024599 RNLS A/C 0.72 -0.018 1.26E-10 0.80 -0.011 1.3E-0 0.011 10<	rs67612840	9	10028826	OFCC1	Α̈́Τ			3.34E-06		-0.015	2.42E-05	-0.013	8.26E-10	4.24	0.398		-0.014	6.40E-26	0.00	4.11E-35
6 113443139 Ú6 T/G 0.20 0.011 191E-04 0.33 0.014 132E-05 0.013 6 13886568 NHSLI T/C 0.36 -0.013 2.90E-07 0.58 -0.015 3.35E-06 -0.014 7 47775053 HUSI T/C 0.34 -0.028 9.25E-18 0.86 -0.024 9.69E-03 -0.018 9 129433929 LMXIB A/G 0.04 -0.010 3.8EE-08 -0.021 1.92E-08 -0.013 10 48388228 RBP3 T/C 0.04 -0.015 3.5E-08 -0.01 1.8E-04 0.07 1.9EE-03 -0.013 10 48388228 RNJS A/C 0.42 -0.018 1.2E-0 0.01 1.3EE-03 -0.014 10 9024599 RALIZ A/C 0.72 -0.018 1.2EE-08 0.04 -0.013 1.2EE-09 0.001 1.3EE-09 0.001 1.3EE-08 0.001 1.2EE-08 0.07 <	rs9366426	9	22064639	CASC15	T/C			2.11E-08		0.012	4.00E-03	0.013	4.42E-10	26.55	0.081	0.43	0.013	9.30E-28	0.00	5.39E-37
6 138869568 NH5L1 T/C 0.36 -0.013 2.90E-07 0.58 -0.015 3.35E-06 -0.014 7 47775053 HUSI T/C 0.84 -0.028 9.25E-18 0.86 -0.024 9.69E-03 -0.013 9 12941331 RPII-9IP771 T/G 0.40 -0.016 3.08E-05 0.007 1.82E-08 -0.017 10 48388228 RBP3 T/C 0.00 NA NA 0.04 -0.015 3.28E-08 0.44 -0.011 1.82E-08 -0.001 10 48388228 RBP3 T/C 0.00 NA NA 0.04 0.011 1.82E-08 0.001 1.82E-08 0.001 1.98E-04 0.001 10 9024599 RRIZ T/C 0.00 NA NA 0.04 0.012 2.47E-06 0.65 0.011 1.45E-03 0.011 10 102824349 KAZALD1 A/C 0.58 0.012 2.47E-06 0.65	rs961755	9	113443139	9/1	1,/G			191F-04	0.33		132F-05	0.013	2.49F-08	000	0.844	0.18	0.014	2.30F-21	000	1.49F-30
7 47775053 HUSI C/G 0.84 -0.028 9.25E-18 0.86 -0.024 9.69E-03 -0.028 8 78941331 RPII-9IP771 T/G 0.40 -0.010 3.08E-05 0.024 9.69E-03 0.0024 9 129433929 LMXIB A/G 0.05 0.024 1.43E-04 0.07 1.82E-08 -0.014 10 48388228 RMP3 T/C 0.04 -0.015 1.25E-08 0.04 -0.017 1.82E-08 -0.014 10 48388228 RMP3 T/C 0.04 -0.018 1.26E-10 0.04 -0.011 1.28E-08 0.04 -0.014 10 90024599 RNIS A/C 0.58 0.012 2.47E-06 0.65 0.011 1.45E-03 0.010 10 90024599 RNIS A/C 0.58 0.012 2.47E-06 0.65 0.011 1.45E-03 0.012 10 90024599 RATGAZDI A/C 0.20 -0	rs4620141	9	138869568	NHS/11	1/C			2.90F-07	0.58		3.35F-06	-0.014	112F-11	19.17	0.164	0.36	-0.008	5.10F-11	5 63	174F-20
8 78941331 RPII-9IPI7.1 T/G 0.40 -0.010 3.08E-05 0.50 -0.017 1.82E-08 -0.013 9 129433929 LMXIB A/G 0.05 0.024 143E-04 0.27 -0.017 1.82E-08 -0.014 9 137433426 COLSAI A/G 0.05 0.015 3.52E-08 0.44 -0.011 7.98E-04 -0.014 10 90024959 RNLS A/G 0.02 NO NA 0.02 0.017 1.48E-04 -0.011 7.98E-04 -0.014 10 90074959 RATI/FRATZ A/C 0.05 0.018 1.24E-00 0.001 1.45E-04 0.011 7.98E-04 -0.014 10 90074959 RATI/FRATZ A/C 0.20 0.018 1.43E-04 0.071 1.82E-08 0.010 10 90074950 RATIORADI A/C 0.20 0.014 4.33E-08 0.011 7.98E-04 0.016 11 217280 A/G	rs12702376		47775053	HUSI	5/Q C/Q			9.25E-18	0.86		9.69E-03	-0.028	3.52E-19	12.45	0.286	0.85	-0.029	2.40E-67	0.00	2.77E-86
9 129433929 LMXIB A/G 0.05 0.024 1.43E-04 0.27 0.021 4.29E-07 0.002 9 137433436 COLSA1 A/C 0.42 -0.015 3.52E-08 0.44 -0.011 7.98E-04 -0.014 10 48388228 RRB3 A/C 0.02 -0.018 1.26E-10 0.001 1.48E-03 -0.014 10 90024599 FRATI/FRATZ/ A/C 0.02 -0.018 1.26E-10 0.001 1.48E-03 -0.016 10 102824349 FRATI/FRATZ/ A/C 0.58 0.012 2.47E-06 0.65 0.013 6.11E-05 0.016 1 2172830 IGEZ C 0.020 2.02E-06 0.51 0.013 6.11E-05 0.015 1 2172830 IGEZ C 0.020 2.02E-06 0.51 0.018 3.56E-07 0.018 1 2172830 IGEZ C 0.020 2.02E-06 0.51 0.018 3.	rs7004112	∞	78941331	RP11-91P17.1	T/G			3.08E-05	0.50	-0.017	1.82E-08	-0.013	4.20E-11	6.85	0.353	0.37	-0.014	1.10E-28	00.00	6.39E-38
9 137433436 COL541 A/C 0.42 -0.015 3.52E-08 0.44 -0.011 7.98E-04 -0.014 10 48388228 RBP3 T/C 0.00 NA NA 0.04 0.071 9.83E-13 0.071 10 90024595 FRATIVEATZ/ A/G 0.72 -0.018 1.26E-10 0.80 -0.012 1.45E-03 -0.016 10 99074959 FRATIVEATZ/ A/C 0.58 0.012 2.47E-06 0.65 0.012 1.45E-03 -0.016 10 102824349 FRAZALD1 A/C 0.50 -0.014 4.33E-06 0.65 0.017 2.47E-06 0.65 0.017 2.47E-06 0.65 0.017 2.47E-06 0.65 0.017 0.015 0.016 0.017 0.016 0.017 0.016 0.017 0.017 0.016 0.011 0.017 0.016 0.017 0.016 0.017 0.016 0.017 0.016 0.017 0.016 0.017 0.016	rs4837104	6	129433929	LMX1B	A/G			1.43E-04	0.27	0.021	4.29E-07	0.022	7.35E-10	0.00	0.956	0.04	0.022	1.90E-12	0.00	2.73E-24
10 48388228 RBP3 T/C 0.00 NA NA 0.04 0.071 9.83E-13 0.071 10 90024599 RNLS A/G 0.72 -0.018 1.26E-10 0.80 -0.012 1.45E-03 -0.016 10 99074959 RRATIVERATZ A/G 0.52 -0.018 1.26E-10 0.80 -0.012 1.45E-03 -0.016 10 102824349 FRAZALD1 C/G 0.67 -0.014 4.33E-06 0.651 -0.015 5.11E-05 0.015 11 2172830 IGFZ A/G 0.20 -0.014 9.53E-06 0.51 -0.015 5.33E-06 -0.015 12 43574200 ADAMTS2O A/G 0.90 0.020 2.02E-06 0.92 0.018 3.50E-03 0.019 13 22980191 SNORD36 I/C 0.26 0.012 2.2E-16 0.80 -0.019 3.50E-03 0.018 13 22980191 SNORD36 I/C <td< td=""><td>rs3132309</td><td>6</td><td>137433436</td><td>COI 5A1</td><td>A/C</td><td>0.47</td><td></td><td>3.52F-08</td><td>0.44</td><td>-0.011</td><td>7.98F-04</td><td>-0.014</td><td>2.27F-10</td><td>000</td><td>0.550</td><td>0.41</td><td>-0.013</td><td>3.10F-24</td><td>000</td><td>7.00F-35</td></td<>	rs3132309	6	137433436	COI 5A1	A/C	0.47		3.52F-08	0.44	-0.011	7.98F-04	-0.014	2.27F-10	000	0.550	0.41	-0.013	3.10F-24	000	7.00F-35
10 90024599 RNIS A/G 0.72 -0.018 1.26E-10 0.80 -0.012 1.45E-03 -0.016 10 99074959 RNIS A/C 0.58 0.012 2.47E-06 0.65 0.012 1.45E-03 -0.016 10 102824349 FRATL/FRATZ/ A/C 0.67 -0.014 4.33E-08 0.49 -0.017 2.02E-07 -0.018 11 2172830 IGFZ A/C 0.20 -0.014 9.53E-06 0.92 -0.015 -0.015 -0.015 -0.014 9.53E-06 0.92 -0.018 3.50E-03 -0.018 12 43574200 ADAMTSZO A/G 0.90 0.020 2.02E-06 0.92 0.018 3.50E-03 0.019 13 22980191 SNORDAS T/C 0.42 -0.020 2.53E-16 0.80 -0.018 3.50E-03 0.019 13 22980191 SNORDAS T/C 0.28 -0.015 2.43E-07 0.09 5.66E-02 -0	rs11204213a	, 6	48388728	RBP3) ()		2	NO I AV	0.04	0.07	9 83F-13	0.071	9.83F-13	00.0	0.223	000	0.063	1 50F-01	00.0	4 36F-13
10 99074959 FRATVFRATZ A/C 0.58 0.012 2.47E-06 0.65 0.013 6.11E-05 0.013 10 102824349 FRATVFRATZ A/C 0.26 -0.014 9.3E-08 0.49 -0.015 2.02E-07 -0.015 11 2172830 IGFZ A/G 0.20 -0.014 9.5E-06 0.51 -0.015 5.3E-06 -0.014 12 43574200 IGAZ A/G 0.20 0.020 2.02E-06 0.51 -0.015 5.3E-06 -0.014 12 43574200 AIAAMTSZO A/G 0.20 -0.020 2.5E-16 0.80 -0.005 5.6E-02 -0.018 13 2234146 FGF9 T/C 0.42 -0.020 2.5E-16 0.80 -0.005 5.6E-02 -0.018 13 22980191 SNORD36 T/C 0.24 0.019 3.0F-14 1.00 NA NA 14 S1856323 STONZ T/C 0.40 0.012 <td>rs166976</td> <td>9</td> <td>90024599</td> <td>RNIS</td> <td>A/G</td> <td></td> <td>018</td> <td>1.26E-10</td> <td>0.80</td> <td></td> <td>1.45E-03</td> <td>-0.016</td> <td>2.47E-12</td> <td>5.52</td> <td>0.378</td> <td>0.73</td> <td>-0.015</td> <td>3.80E-30</td> <td>0.00</td> <td>4.17E-44</td>	rs166976	9	90024599	RNIS	A/G		018	1.26E-10	0.80		1.45E-03	-0.016	2.47E-12	5.52	0.378	0.73	-0.015	3.80E-30	0.00	4.17E-44
10 102824349 KAZALD1 C/G 0.67 -0.014 4.33E-08 0.49 -0.017 2.02E-07 -0.015 10 2172830 IGAZ C/G 0.67 -0.014 9.33E-08 0.49 -0.017 2.02E-07 -0.015 12 43574200 IGAZ A/G 0.90 0.020 2.02E-08 0.92 0.018 3.56E-02 -0.014 13 22347368 HMGA2 1/G 0.42 -0.020 2.53E-16 0.80 -0.009 5.66E-02 -0.018 13 2234736 HMGA2 1/C 0.42 -0.020 2.53E-16 0.80 -0.009 5.66E-02 -0.018 13 22980191 SNORD36 1/C 0.28 -0.015 2.43E-07 0.48 -0.019 5.66E-02 -0.018 14 2847616 INTS6 1/C 0.40 0.015 2.43E-07 0.48 -0.010 1.63E-03 0.011 14 81856323 STON2 1/C <t< td=""><td>rs10786330</td><td>9</td><td>99074959</td><td>FRATI/FRATZ/</td><td>YC Y</td><td>0.58</td><td>0.012</td><td>2.47E-06</td><td>0.65</td><td></td><td>6.11E-05</td><td></td><td>1.22E-09</td><td>0.00</td><td>0.980</td><td>0.60</td><td>0.008</td><td>4.00E-12</td><td>1.93</td><td>1.54E-19</td></t<>	rs10786330	9	99074959	FRATI/FRATZ/	YC Y	0.58	0.012	2.47E-06	0.65		6.11E-05		1.22E-09	0.00	0.980	0.60	0.008	4.00E-12	1.93	1.54E-19
10 102824349 KAZALD1 C/G 0.67 -0.014 4.33E-08 0.49 -0.017 2.02E-07 -0.014 11 2172830 IGFZ A/C 0.20 -0.014 9.53E-06 0.51 -0.015 5.33E-06 -0.014 12 43574200 ADAMTS2O A/C 0.20 -0.014 9.53E-06 0.51 -0.015 5.33E-06 -0.014 13 2234146 FGF9 T/C 0.64 0.019 3.07E-14 1.00 NA NA 13 22980191 SNORD36 T/C 0.28 -0.015 2.43E-07 0.48 -0.010 1.63E-03 0.019 14 25407080 INTS6 T/C 0.40 0.015 2.16E-09 0.53 0.01 1.63E-05 0.01 14 81856323 STON2 T/C 0.11 1.91E-06 0.34 0.011 1.4E-04 0.012 15 48755168 FBN1 T/C 0.40 0.016 1.31E-08				ARHGAP19	•															
11 2172830 IGFZ A/C 0.20 -0.014 9.53E-06 0.51 -0.015 5.33E-06 -0.014 12 43574200 ADAMTS20 A/G 0.90 0.020 2.02E-06 0.92 0.018 3.50E-03 0.019 12 64347368 HMGA2 T/G 0.42 -0.020 2.53E-16 0.09 5.6E-02 -0.018 13 2234146 FGF9 T/C 0.24 -0.015 2.43E-07 0.09 5.6E-02 -0.018 13 22980191 SVORD36 T/C 0.24 -0.015 2.43E-07 0.48 -0.010 1.63E-02 -0.018 14 25447080 SYXBP6 T/C 0.40 0.015 2.16E-09 0.53 0.013 4.27E-05 0.013 14 81856323 STON2 T/C 0.11 0.021 1.91E-06 0.34 0.011 1.4E-04 0.013 15 7909528 FBMI T/C 0.17 -0.009 1.68E-03	rs807037	10	102824349	KAZALD1	C/6	0.67		4.33E-08	0.49	-0.017	2.02E-07	-0.015	1.43E-13	0.00	0.631		-0.017	9.10E-42	0.00	7.12E-54
12 43574200 ADAMTS20 A/G 0.90 0.020 2.02E-06 0.92 0.018 3.50E-03 0.019 12 66347368 HMGA2 T/G 0.42 -0.02 2.53E-16 0.80 -0.009 5.66E-02 -0.018 13 22980191 SNORD36 T/C 0.64 0.019 3.07E-14 1.00 NA NA 0.019 13 22980191 SNORD36 T/C 0.28 -0.015 2.43E-07 0.49 0.013 3.01E-08 -0.001 1.65E-03 0.013 14 25447080 STXBP6 T/C 0.11 0.021 3.21E-08 0.07 1.65E-03 0.013 14 81856323 STON2 A/G 0.31 0.012 1.91E-06 0.34 0.011 7.14E-04 0.012 15 7895282 ADAMTS7 T/C 0.77 -0.009 1.68E-03 0.012 1.21E-03 0.012 18 32643292 AMAPRE2 T/C 0.34	rs7948458	Ħ	2172830	IGF2	A/C	0.20		9.53E-06	0.51	-0.015	5.33E-06	-0.014	4.90E-10	40.44	0.008	0.19	-0.016	6.50E-26	0.00	1.66E-36
12 66347368 HMGA2 T/G 0.42 -0.020 2.53E-16 0.80 -0.009 5.66E-02 -0.018 13 2234146 FGF9 T/C 0.64 0.019 3.07E-14 1.00 NA NA 0.019 13 22980191 SNORDA36 T/C 0.28 -0.015 2.43E-07 0.38 -0.013 1.6E-09 0.013 4.2FE-05 0.013 14 S1826323 STXBP6 T/C 0.11 0.021 3.1E-08 0.07 0.024 4.5E-05 0.014 15 48755168 FBN1 T/C 0.1 1.91E-06 0.34 0.011 7.14E-04 0.012 15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.67 -0.018 1.49E-07 0.012 15 7909528 ADAMTST T/C 0.40 0.016 3.08E-09 0.18 1.29E-03 0.012 20 55821046 BMP7 T/C 0.31	rs11181913	12	43574200	ADAMTS20	A/G	06.0		2.02E-06	0.92	0.018	3.50E-03	0.019	3.30E-08	0.00	0.645	0.91	0.016	4.40E-14	0.00	1.03E-22
13 22314146 FGF9 T/C 0.64 0.019 3.07E-14 1.00 NA NA 0.019 13 22980191 SNORD36 T/C 0.28 -0.015 2.43E-07 0.48 -0.010 1.63E-03 -0.013 14 25407080 SIXBP6 T/C 0.40 0.015 2.11E-08 0.07 0.024 4.5E-05 0.011 15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.01 1.4E-04 0.012 18 32643223 STON2 T/C 0.77 -0.009 1.68E-03 0.67 -0.014 4.5E-05 0.011 15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.67 -0.018 1.49E-07 -0.012 18 3264329 MAPRE2 T/C 0.40 0.016 3.08E-09 0.31 1.21E-03 0.012 18 3264329 ADARRE2 T/C 0.40 0.016 3.08E-09	rs7959830	12	66347368	HMGA2	1/G	0.42		2.53E-16	0.80	-0.009	5.66E-02	-0.018	3.02E-16	34.50	0.027		-0.018	3.30E-17	5.41	9.35E-47
13 22980191 SNORD36 T/C 0.28 -0.015 2.43E-07 0.48 -0.010 1.63E-03 -0.013 13 52006645 INT36 T/C 0.40 0.015 2.16E-09 0.53 0.013 4.27E-05 0.014 14 25447080 STXBP6 T/C 0.11 0.021 3.1E-08 0.07 0.024 4.5E-05 0.014 15 48755168 FBNT T/C 0.77 -0.09 1.68E-03 0.01 7.4E-04 0.012 15 79095281 FBNT T/C 0.77 -0.009 1.68E-03 0.03 1.49E-07 -0.012 18 32643292 AAAPRE2 T/C 0.40 0.016 2.19E-05 0.18 0.021 1.26E-04 0.010 20 55821046 BMP7 T/G 0.29 -0.020 2.19E-05 0.82 -0.021 2.63E-04 -0.020 21 47427165 COL647 T/C 0.29 -0.016 1.71E-0	rs9506725 ^a	13	22314146	FGF9	1/C	0.64		3.07E-14	1.00		AN	0.019	3.07E-14	0.33	0.456		0.020	5.10E-59	0.00	1.21E-78
13 52006645 INTS6 T/C 0.40 0.015 2.16E-09 0.53 0.013 4.27E-05 0.014 14 25447080 STXBP6 T/C 0.11 0.021 3.21E-08 0.07 0.024 4.55E-05 0.021 15 81856323 STON2 A/G 0.31 0.012 1.91E-06 0.34 0.011 7.4E-04 0.012 15 74875168 FBNI T/C 0.77 -0.009 1.68E-03 0.07 1.49E-07 -0.012 15 7909528 ABAMTS7 T/C 0.40 0.020 2.19E-08 0.03 1.21E-03 0.014 18 32643292 ABAPRE2 T/C 0.93 -0.020 2.19E-03 0.021 1.21E-03 0.015 20 55821046 BMP7 T/C 0.29 -0.016 1.71E-08 0.021 1.11E-03 0.017 21 47427165 COL647 T/C 0.29 -0.016 1.71E-08 0.22 -0.02	rs9316971	13	22980191	SNORD36	T/C	0.28		2.43E-07	0.48	010	1.63E-03	-0.013	3.21E-09	32.34	0.044		-0.009	2.20E-12	1.91	3.51E-21
14 25447080 STXBP6 T/C 0.11 0.021 3.21E-08 0.07 0.024 4.55E-05 0.021 14 81856323 \$70N2 A/G 0.31 0.012 1.91E-06 0.34 0.011 7.14E-04 0.012 15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.67 -0.018 1.49E-07 -0.012 15 78095287 ADAMTS7 T/C 0.40 0.016 3.08E-09 0.18 1.21E-03 0.016 18 3.2643292 MAPRE2 T/C 0.93 -0.020 2.19E-03 0.021 1.21E-03 0.017 20 5.5821046 BMP7 T/G 0.29 -0.016 1.71E-08 0.021 1.11E-03 0.017 21 4.7427165 COL6A1 T/C 0.29 -0.016 1.71E-08 0.022 9.43E-05 -0.017	rs7327381	13	52006645	INTS6	1/C	0.40		2.16E-09	0.53		4.27E-05	0.014	8.06E-13	0.00	0.829		0.012	1.50E-23	0.00	3.74E-34
14 81856323 STON2 A/G 0.31 0.012 1.91E-06 0.34 0.011 7.14E-04 0.012 15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.67 -0.018 1.49E-07 -0.012 15 78095287 ADAMTSZ T/C 0.40 0.016 3.08E-09 0.08 1.21E-03 0.015 20 55821046 BMPZ T/G 0.33 0.017 4.88E-11 0.16 0.021 1.1E-03 0.017 21 47427165 COL647 T/C 0.29 -0.016 1.71E-08 0.022 0.021 1.1E-03 0.017	rs75772222	7	25447080	STXBP6	T/C	0.11		3.21E-08	0.07		4.55E-05	0.021	1.28E-11	0.00	0.983		0.020	5.00E-27	0.00	9.79E-38
15 48755168 FBN1 T/C 0.77 -0.009 1.68E-03 0.67 -0.018 1.49E-07 -0.012 15 79095287 ADAMTS7 T/C 0.40 0.016 3.08E-09 0.18 0.021 1.21E-03 0.016 18 32643292 MAPRE2 T/C 0.93 -0.015 2.19E-05 0.18 0.021 1.21E-03 0.016 20 55821046 MMP7 T/G 0.33 0.017 485E-11 0.16 0.021 1.1E-03 0.017 21 47427165 COL6A1 T/C 0.29 -0.016 1.71E-08 0.22 -0.022 9.43E-05 -0.017	rs4083463	7	81856323	STON2	A/G	0.31		1.91E-06	0.34		7.14E-04	0.012	7.92E-09	4.26	0.397	0.33	0.010	2.00E-16	0.00	3.12E-24
15 79095287 ADAMTS7 T/C 0.40 0.016 3.08E-09 0.18 0.021 1.2IE-03 0.016 18 32643292 MAPRE2 T/C 0.93 -0.020 2.19E-05 0.82 -0.021 2.63E-04 -0.020 2.055821046 BMP7 T/G 0.33 0.017 4.85E-11 0.16 0.021 1.11E-03 0.017 21 47427165 COL6A1 T/C 0.29 -0.016 1.71E-08 0.22 -0.022 9.43E-05 -0.017	rs9806595	15	48755168	FBN1	T/C	0.77	-0.009	1.68E-03	0.67	-0.018	1.49E-07	-0.012	2.23E-08	0.00	0.691	0.77	-0.004	4.20E-03	10.40	6.43E-09
18 32643292 MAPRE2 1/C 0.93 -0.020 2.19E-05 0.82 -0.021 2.63E-04 -0.020 3 20 55821046 BMP7 1/G 0.33 0.017 4.85E-11 0.16 0.021 1.11E-03 0.017 3 21 47427165 COL6A1 1/C 0.29 -0.016 1.71E-08 0.22 -0.022 9.43E-05 -0.017 1	rs4887113		79095287	ADAMTS7	1/C	0.40	0.016	3.08E-09	0.18	0.021	1.21E-03	0.016	2.57E-11	0.00	0.798	0.45	0.012	1.60E-24	2.11	5.74E-38
20 55821046 BMP7 T/G 0.33 0.017 4.85E-11 0.16 0.021 1.11E-03 0.017 3 21 47427165 COL6A1 T/C 0.29 -0.016 1.71E-08 0.22 -0.022 9.43E-05 -0.017 1	rs184926585		32643292	MAPRE2	1/C	0.93	020	2.19E-05	0.82	-0.021	2.63E-04	-0.020	3.61E-08	0.00	0.756	0.92		1.30E-03	11.53	4.86E-11
21 47427165 COL6A1 T/C 0.29 -0.016 1.71E-08 0.22 -0.022 9.43E-05 -0.017 1	rs6064518	20	55821046	BMP7	5/1	0.33	710	4.85E-11	0.16	0.021	1.11E-03	0.017	3.47E-13	0.00	0.809	0.32	0.013	1.20E-24	2.15	6.73E-40
	rs13050142	21	47427165	COL6A1	1/C	0.29	-0.016	1.71E-08	0.22	-0.022	9.43E-05		1.86E-11	0.00	0.964	0.31	-0.013	4.80E-25	1.87	2.45E-40

Lead variants shown were genome-wide significant (P < 5.0E-8) in subjects of CREAM of European and Asian ancestry (Stage 1), with results of replication in UK Biobank data (Stage 2). Variants in bold indicate new loci.

She programment of programments were gene in 200 kb flanking the lead SNP based on NCBI build 37; A7 effect allele, A2 reference allele, EAF effect allele frequency, p effect size of corneal curvature in millimeter based on the effect allele A1; Het-P? A2 reference seffect allele frequency, p effect size of corneal curvature in millimeter based on the effect allele A1; Het-P? A2 reference seffect p P(N) between the Studies.

**Lead SNPs identified were monomorphic/extremely rare in Europeans or Asian populations.

(rs1800813; $P = 1.59 \times 10^{-73}$), and HDAC11/FBLN2 (rs2630445; $P = 4.92 \times 10^{-67}$). The RSPO1 gene was previously identified as the strongest locus with the same lead SNP rs4074961 associated with AL in CREAM¹⁶. Here it stands out as the most significant locus for CC in our large meta-analysis. We confirmed associations with CC in the four previously identified loci in our samples: PDGFRA, MTOR, RBP3, and $CMPK1^{11,17-19}$, and in an additional 17 loci provisionally identified in the European emmetropes from the UK Biobank²⁰. In total, we identified 20 novel CC loci through single-variant analysis.

Following the age classification scheme adopted by the CREAM consortium, we stratified the CREAM samples into younger (age < 25 years) and older (age \ge 25 years) groups. In the older group (n=35,442), the top five genome-wide significant loci were RSPO1, MTOR, PDGFRA1, HUS1, and FGF9 (Supplementary Data 1). There were no novel genome-wide significant hits for CC in both groups. No variants reached genome-wide significance in the younger group (n=8620), likely due to the insufficient power in contrast to the older group. The effect sizes and directions of effect for the top variants were consistent between the younger and older groups.

Trans-ethnic comparison of genotypic effects in Europeans versus Asians. Among the 41 lead variants identified in the full discovery samples, the effect size and direction of effect were largely consistent across Europeans and Asians (Table 1). To evaluate whether genetic effect sizes were consistent in Europeans versus Asians in the CREAM samples, we compared additive effect sizes (beta coefficient in millimetre per allele) of variants with *p*-value < 0.01 in both populations. We grouped these variants by inter-population allele frequency discrepancy between the two ancestry groups (<0.1, 0.1–0.3, and >0.3). Overall, the variants were concordant in direction of effects and effect sizes (Fig. 2a–c). The effect sizes appeared most consistent in variants with little discrepancy in allele frequency (2a; allele frequency difference < 0.1), and less consistent in variants of larger allele frequency discrepancy (2c; allele frequency difference > 0.3).

The high concordance of genetic effects between Europeans and Asians, however, could not rule out the possibility of discrepancy at some loci with large inter-population differences in the allele frequency and LD structure. Three loci in our all-ancestry analyses were driven by European populations (HDAC11/FBLN2 rs2630445, ADAMTS19/CASY3 rs7708378, and




Fig. 2 Concordance of effect sizes of variants between European and Asian populations and loci showing population-specific signals. a-c For each scatter plot, effect size in Asians (x-axis) and in Europeans (y-axis) was plotted for variants with P < 0.01 in both ancestry groups in CREAM. The variants were grouped based on the allele frequency difference between European and Asian populations: **a** < 0.1; **b** 0.1-0.3, and **d** > 0.3. The red dot represents variants with $P < 1.0 \times 10^{-7}$ in the meta-analysis of combined population, and green circle indicates variant with $1.0 \times 10^{-7} < P < 0.01$ in both Europeans and Asians. Dashed line in red is the fitted line and in grey is the x = y line of unity. **d-i** Regional plots in CREAM Europeans (**d-f**) and Asians (**g-i**) showing population-specific signals at loci exhibiting allele frequency differences: HDAC11/FBLN2 (**d, g**), CMPK1/STIL (**e, h**) and **c** FGF9 (**f, i**). Here we present regional plots for three lead variants. (i) Lead variant rs2630445 in plot **d** showing genome-wide association signals in Europeans (MAF = 0.10) is monomorphic in Asian populations. (ii) Lead variant rs60078183 in plot **h** exhibiting association in Asians (MAF = 0.21) is monomorphic in European populations. (iii) Lead variant rs9506725 in plot **f** showing association in Europeans (MAF = 0.36) is monomorphic in Asian populations.




Fig. 3 Effect sizes on cornea curvature, axial length and spherical equivalent for CC-associated variants. Corneal curvature (CC)-associated genetic variants identified from CREAM (n = 44,042) were grouped based on the patterns of the associations of effect alleles with axial length (AL; n = 10,851) and spherical equivalent (n = 95,505). Group A—variants associated with AL only ('eye-size' determining genetic variants); the effect allele of each variant was associated with eye size: a larger eye with both a flatter CC and longer AL (positive β on both CC and AL; bar in red), and a smaller eye with both a steeper CC and shorter AL (negative β; bar in blue). These variants were not associated with spherical equivalent. Group B—variants associated with spherical equivalent; the allele associated with a steeper CC was associated with a more negative refractive error (or vice versa). These variants were not associated with AL, except those at loci *IGFBP5/TNP1, HUS1, RP11-91P17.1*, and *FGF9.* Group C—variants not associated with spherical equivalent or AL. For the associations with axial length and spherical equivalent, *FDR* < 0.01 was considered significance. The colour of the bar represents a positive genetic effect (in red) or a negative genetic effect (in blue).

FGF9 rs9506725), and two loci were driven by Asian populations (RBP3 rs11204213 and CMPK1/STIL rs60078183). In the ethnic group (either the Asian or European populations) where these variants were not associated, they typically presented as monomorphic in the other ethnic group, as well as those variants in LD with the lead variant $(r^2 \ge 0.8;$ Supplementary Data 2). Regional plots at HDAC11/FBLN2 rs2630445, CMPK1/STIL rs60078183, and FGF9 rs9506725 were presented in Europeans (Fig. 2d-f) and Asians (Fig. 2g-i), respectively, with interpopulation allele frequency at 0.10, 0.20, and 0.36. The proxy SNPs adjacent showed minimal significance at only two loci in Asians (HDAC11/FBLN2 rs2655225, $P = 3.34 \times 10^{-3}$, $r^2 = 0.62$) and ADAMTS19/CASY3 rs11746536; $P = 2.67 \times 10^{-4}$, $r^2 = 0.11$; Supplementary Table 3). For GWAS analyses performed separately in Europeans and Asians, there were two Asianspecific loci (*EMX2/EMX2OS* rs2240776, $P = 2.45 \times 10^{-8}$; NCAPG rs7672919, $P = 3.90 \times 10^{-8}$; Supplementary Table 4); both did not reach genome-wide significance in the combined analysis. In addition, one locus showing suggestive significance in CREAM Europeans (*PIEZO2* rs2101976; $P = 7.32 \times 10^{-8}$) has been replicated in the UK Biobank data ($P = 8.90 \times 10^{-14}$).

We calculated SNP-heritability (SNP- h^2) using GWAS summary statistics²². The SNP- h^2 estimate for CC in Asians (0.196, s.e. = 0.036) was numerically lower than in Europeans (0.267, s.e. = 0.024), but there was no statistical evidence for a meaningful difference. A similar pattern was noted in a previous study¹².

Association of corneal curvature loci with spherical equivalent and axial length. In further analyses, we assessed the associations of the 41 CC lead variants with spherical equivalent ^{14,15} in 95,505 participants from the UK Biobank, as well as in a subset of

CREAM participants with AL measurement (N=10,851; Supplementary Table 5). The lead variants were categorized into the following three groups using false discovery rates (FDR) set at a threshold of 1% from the Benjamini-Hochberg procedure²³ (Fig. 3 and Supplementary Data 3).

Eight CC variants were associated with AL, but not spherical equivalent (Group A, Fig. 3). That is, the effect allele of the variant was associated with eye size, e.g. a larger eye with both a flatter CC and longer AL (positive genetic effects on both CC and AL; bar in red, Fig. 3) or a smaller eye with both a steeper CC and shorter AL (negative genetic effects; bar in blue), but was not associated with spherical equivalent. For instance, HMGA2 rs7959830 T allele was associated with a steeper CC (β = -0.018, s.e. = 0.002, $P = 3.02 \times 10^{-16}$) and shorter AL ($\beta =$ -0.047, s.e. = 0.014, $P = 6.54 \times 10^{-4}$), but not spherical equivalent ($\beta = 0.005$, s.e. = 0.013, P = 0.670). A lack of association with refractive error at these variants might be explained on the basis of the compensatory effects resulting in, a steeper CC (that tends to make the eye more myopic) and shorter AL (that tends to make the eye more hyperopic/less myopic), or a flatter CC and longer AL The compensatory genetic effects for CC and AL relevant to the effects on myopia or hyperopia is illustrated in Fig. 4. Among these variants, the pleiotropic association on AL of HDAC11/FBLN2 rs2630445, ADAMTS19/CHSY rs7708378 were mainly driven from European populations, and RBP3 rs11204213 from Asian populations.

Fifteen CC variants were associated with spherical equivalent (Group B, Fig. 3). Eleven of these variants were not associated with AL. The strongest signals associated with spherical equivalent $(P < 1 \times 10^{-7})$ were CASC15 rs9366426, CHRND/PRSS56 rs2245601, KAZALD1 rs807037, FBN1 rs9806595, and




Fig. 4 Illustration of pleiotropic effect ratio $\frac{\beta_{AL}}{\beta_{CC}}$ and effects toward emmetropic and myopic states. The figure illustrates genetic effects of AL (β_{AL}) might or might not compensate genetic effects of corneal curvature (β_{CC}) toward myopia or hyperopia. Longer CC (shown by positive β_{CC} ; arrow upward) tends to make the eye hyperopic (dashed line in blue) and longer AL (positive β_{CC} ; arrow downward) tends to make the eye more myopic (dashed line in red). Similarly, steeper CC (negative β_{CC} , arrow downward) tends to make the eye more myopic and shorter AL (negative β_{CC} ; arrow downward) tends to make the eye less myopic. The compensatory pleiotropic effects β_{AL} could offset β_{CC} on myopia or hyperopia at the pleiotropic ratio $\frac{\beta_{AL}}{\beta_{CC}}$ ~ 3, as shown in group A. The compensatory pleiotropic effects β_{AL} , however, cannot offset β_{CC} on myopia or hyperopia at smaller pleiotropic ratio $\frac{\beta_{AL}}{\beta_{CC}}$, as shown in group B. There might be other pleiotropic effect in Group C, besides AL, to compensate genetic effect of CC on myopia. Het-I2, for heterogeneous effects between the variants. All P-value for heterogeneity was >0.05. Pleiotropic effect ratio was calculated at each variant and combined to estimate $\frac{\beta_{AL}}{\beta_{CC}}$ and heterogeneity using the meta-analysis approach (see Methods). Grouping of A, B, and C was the same as in Fig. 3.

RNLS rs166976. Among these 11 variants, the allele associated with a steeper CC was associated with a more negative/myopic refractive error (or a flatter CC and more positive/hyperopic refractive error). For instance, FBN1 rs9806595 T allele was associated with a steeper CC ($\beta = -0.012$, s.e. = 0.002, $P = 2.23 \times$ 10^{-8}) and more myopic refractive error ($\beta = -0.084$, s.e. = 0.014, $P = 1.40 \times 10^{-8}$), but not AL ($\beta = -0.015$, s.e = 0.013, P = 0.231). For the remaining CC variants at four loci that were associated spherical equivalent as well as AL (HUS1, RP11-91P17.1, FGF9, and IGFBP5/TNP1), the direction of genetic effect on spherical equivalent may depend on the relative magnitude of effect on CC versus AL. For instance, although both HUS1 rs12702376 C allele and RP11-91P17.1 rs7004112 T allele were associated with steeper CC (that tends to make the eye more myopic) and shorter AL (that tends to make the eye less myopic), HUS1 was associated with a negative/myopic refractive error, while RP11-91P17.1 was associated with a positive/hyperopic refractive error. Among these variants, pleiotropic effects of FGF9 rs9506725 were mainly driven from European populations.

The remaining 18 CC variants (Group C, Fig. 3) were not associated with spherical equivalent or AL at FDR > 1%. The association on CC and spherical equivalent at the majority loci was, although not significant, in an expected direction, e.g. with a steeper CC and a more negative/myopic refractive error (or vice versa). Among these variants, *CMPK1/STIL* rs60078183 was mainly driven by Asian populations. The pleiotropic genetic effects on spherical equivalent of CC-associated variants, together with previously implicated AL variants ^{16,24}, are summarized in Supplementary Fig. 5.

The pleiotropic effect ratio $\frac{\beta_{AL}}{\beta_{CC}}$ was meta-analyzed across all variants in each group (Fig. 4; Supplementary Table 6). The pleiotropic ratio $\frac{\beta_{AL}}{\beta_{CC}}$ in group A (2.92, 95% CI: 2.37–3.48) was larger than that in group B (1.66, 95% CI: 1.16-2.16) and C (1.19, 95% CI: 0.78–1.61), with p-value at 7.56×10^{-4} and 1.68×10^{-6} , respectively. For variants in group A, the pleiotropic effect for AL could offset genetic effect for CC towards myopia or hyperopia; namely, a genetically determined 1 mm increase (or decrease) for CC accompanied by a 2.92 mm increase (or decrease) on average for AL might cancel out their respective opposite effects on refractive error. In contrast, if the pleiotropic effects on AL could not compensate effects on CC, as shown in Group B, these variants may influence refractive error primarily through the net effect of CC. The interplay between AL, CC and refractive error at the variants in Group C is less clear, likely these variants might have pleiotropic effect for other endophenotypes, besides AL, to account for the genetic effects of CC on refractive error.

Post GWAS gene-based and pathway analyses. We applied gene-based tests using the Versatile Gene-based Association Study (VEGAS)^{25,26}, with Bonferroni corrected *p*-value at 2.09×10^{-6} to test 24,000 genes for significance. Over and above the loci found in the per-variant tests, six additional genomic regions were significantly associated with CC via gene-based tests (Supplementary Table 7): ANKRD65 ($P = 9.0 \times 10^{-7}$), PEAR1 ($P = 1.57 \times 10^{-7}$), ASB1 ($P = 2.54 \times 10^{-7}$), GMDS ($P = 2.48 \times 10^{-8}$), EMX2OS ($P = 4.84 \times 10^{-8}$), and HM13-AS1 ($P = 2.18 \times 10^{-7}$).

We further conducted gene-set analysis using VEGAS by testing whether CC genes shared a common function or operated in the same pathways (see Methods). Thirty pathways were identified at Bonferroni corrected *p*-value of 5.14×10^{-6} (Supplementary Data 4), with those involving proteinaceous extracellular matrix (ECM) (GO: 0005578; $P = 1.05 \times 10^{-9}$) and ECM (GO: 0031012, $P = 7.53 \times 10^{-9}$) being the top two. The other significant pathways included gene sets involved in eye development (GO:0001654; P = 4.00×10^{-7}) and camera-type eye development, GO: 0043010, P = 3.20×10^{-6}), as well as those involving in organ morphogenesis (GO:0009887; $P = 4.86 \times 10^{-7}$), skeletal system development (GO:0001501; $P = 5.25 \times 10^{-7}$) and the Wnt signalling pathway (KEGG:04310, $P = 2.09 \times 10^{-6}$). For the top 41 loci identified in this study plus genes previously reported for CC (WNT7B24 and ZNRF316), we conducted gene-set analysis using g: Profiler (https://biit.cs.ut.ee/gprofiler/gost) and identified 48 significant pathways at multiple testing corrected p-value of 0.05. Among these, collagen-containing ECM (GO: 0062023; $P = 2.72 \times 10^{-7}$) and ECM (GO: 0031012; $P = 6.51 \times 10^{-6}$) were the most significant terms (Supplementary Data 5). Other significant pathways consisted of heparin binding (GO: 0062023; $P = 6.95 \times 10^{-5}$), embryonic morphogenesis (GO: 0048598; $P = 3.99 \times 10^{-4}$), glycosaminoglycan binding (GO: 0005539, $P = 6.86 \times 10^{-4}$), and skeletal system development (GO: 0001501; $P = 1.11 \times 10^{-3}$) etc.

To visualize functional enrichment of identified gene-sets, we mapped these sets graphically into an enrichment network²⁷ in Cytoscape²⁸. Similarity coefficients greater than 0.375 were used to place these sets together with the interconnectivity drawn by a line. Using comprehensive collections of gene-sets related to CC, we identified enrichments in gene-sets involved in organism development and growth, with components for eye development and connective tissue cartilage, explicitly suggesting a strong genetic link between the size of the eye and organism/body (Fig. 5). We also observed that gene-sets were involved in ECM and glycosylation protein activity, which have previously been suggested in pathways related to central corneal thickness²⁹.

To assess any specific roles of subset of CC genes with pleiotropic effects on myopia, we performed gene-set clustering.




Fig. 5 Gene-set enrichment analysis for corneal curvature in CREAM data. Enrichment results were mapped as a network of gene-sets (nodes) related by mutual overlap (edges). Node size is proportional to the total number of genes in each set, colour gradient represents the enrichment significance and edge thickness represents the number of overlapping genes between sets. Nodes in red represent gene-sets identified from the g:Profiler enrichment analysis, and in green represent additional gene-sets identified from the VEGAS-pathway analysis. Nodes of diamond show the pathways for the implicated genes associated with both CC and spherical equivalent (Group 2 in Fig. 3). Groups of functionally related gene-sets are circled and labelled (dashed line).

Enriched pathways identified included basement membrane, endoplasmic reticulum lumen, collagen-containing extracellular matrix, ossification, and osteoblast differentiation (Fig. 5; Diamond node; Supplementary Data 5). The pathways were closely connected to ECM or developmental process, thus underlying a functional heterogeneity in genes exhibiting pleiotropic effects on both CC and refractive error.

Additional pathways identified from the whole-genome data using VEGAS, such as elastic fibre formation, camera-type eye development and O-linked Glycosylation, also displayed connectivity to the ECM, development processes and glycosylation protein activity (Fig. 5; nodes in green). A few pathways (regulation of stem cell differentiation, system development, etc.) failed to link to any existing gene-sets were identified; this is likely attributable to marginal and uncharacterized CC-genes.

Biological function of the CC-associated loci. We examined gene expression in 20 normal human donor eyes from the ocular tissue database (OTDB; https://genome.uiowa.edu/otdb/). The majority of the genes identified at the 41 loci were expressed in human ocular tissues including cornea, sclera, ciliary body, or lens etc. (Supplementary Data 6). *THBS4* had the highest expression in the cornea and sclera, *IGFBP5* in the ciliary body and sclera, and *PDGFRA* in the lens.

We also queried expression quantitative trait loci (e-QTL) database to assess the association between the gene expression and the top CC-variants in different human tissues (see UTLs). Twenty-one index variants were eQTLs for the expression of genes, which resided in, or were adjacent to, the variant (Supplementary Data 7). Among them, the majority of variants were eQTL's for the expression of the nearest gene. There are some

exceptions. For example, SNP rs807037 is a missense variant within the *KAZALD1* gene and is also an eQTL for the nearby gene *SFXN3* in artery, brain, adipose subcutaneous and nerve tissues $(P < 2.20 \times 10^{-5})$. Intronic *MTOR* rs3737611 is an eQTL for *EXOSC10* in thyroid, nerve and artery tissues $(P < 5.70 \times 10^{-5})$. Intronic *RSPO1* rs4074961 is an eQTL for itself and nearby genes *GNL2*, *DNALI1* and *MEAF6* in various tissues.

The newly identified genes are largely involved in ocular growth/development. *LMX1B* (encoding a LIM homeodomain class transcription factor) regulates anterior segment morphogenesis and patterning³⁰, and is associated with Nail-Patella syndrome³¹. Recently, *LMX1B* has been reported to be associated with primary open-angle glaucoma, accompanied by development defects of the ocular anterior segments including cornea^{32–34}. *SOX2* (encoding a member of the SRY-related HMG-box family of transcription factors) links to both anophthalmia and microphthalmia³⁵. Other CC genes that are also associated with eye or overall morphology include *GHSR* (associated with craniofacial development³⁶), *HMGA2* (linked to body height), and *LCORL* (linked to skeletal trunk height³⁷).

Five of the implicated genes (*ADAMTS3*, *ADAMTS6*, *ADAMTS7*, *ADAMTS19*, and *ADAMTS20*) belong to the ADAMTS protein family, which is closely involved in regulating the organization and function of ECM³⁸. For instance, *ADAMTS6* has a major role in focal adhesion and tight junction formation, and can alter the deposition of fibrillin microfibrils in epithelial cells³⁹. Interestingly, ADAMTS family members also associate with height variation (*ADAM28*, *ADAMTS19*, *ADAMTS2*, *ADAMTS3*, *ADAMTS6*, *ADAMTSL1*, *ADAMTSL3*), suggesting their pleiotropic roles in body growth⁴⁰.

A cluster of novel genes are involved in both ECM and organism/eye development. For instance, FBN1 encodes the

ECM protein fibulin-1, which modulates corneal cell migration by interactions with other ECM components, such as fibronectin⁴¹. Weill-Marchesani syndrome (that may be associated with thicker and steeper corneas) may also result from dominant mutations in FBN1. Fibronectin and IGFBP5 also bind to each other. This binding regulates the ligand-dependent action of IGFBP5 on insulin-like growth factors, and this has effects on cell proliferation, differentiation, survival, and motility. IGFBP5 shows expression in the human cornea and was down regulated in eyes with keratoconus^{42,43}. BMP7 encodes a member of the transforming growth factor -β superfamily that is involved in numerous cellular functions including development, morphogenesis, cell proliferation, apoptosis, and ECM synthesis⁴⁴. BMP7 is key in eye development during embryogenesis, and BMP7knockout mice have been shown to develop anophthalmia^{45,46}. OFCC1 (encoding a reticular cytoplasmic protein expressed during embryonic development) in the Medaka fish is associated with the ojoplano ('flat eye') phenotype due to defective eye cup morphogenesis⁴⁷. COL5A1 and COL6A1 encode components of type V and VI fibrillar collagens that are present in the human cornea⁴⁸. COL6A1, together with ADAMTS20, have been reported to be associated with intraocular pressure⁴⁹. COL5A1 mutations are found in classical Ehlers-Danlos Syndrome⁵⁰, which is associated with thinner and steeper corneas⁵¹. COL5A1 is also a susceptibility locus for central corneal thickness^{52,53}. THBS4 encodes an extracellular calcium binding protein that is involved in cell proliferation, adhesion, and migration⁵⁴. FGF9 is involved in the neural patterning of the optic neuroepithelium⁵⁵.

Genes identified as being involved in the Wnt signaling pathway were also implicated in our analysis (*SOX2*, *FRAT1*, *FRAT2*, *RSPO1*, *FGF9*; Supplementary Data 5 "canonical Wnt signaling pathway"). Two additional Wnt signalling related genes (*ZNRF3*¹⁶ and *WNT7B*²⁴), though not the top genes in this study, were also identified as being associated with CC or axial length. The Wnt signalling pathway has prominent effects on multiple developmental events during embryogenesis⁵⁶, including that of differentiation of the anterior segment of the eye^{57,58}, and retinal development^{59,60}.

Discussion

In the largest CREAM trans-ethnic GWAS meta-analysis of CC to date (44,042 individuals with replication in 88,218 participants from UK Biobank), we identified novel loci through single-variant analysis, and gene-based tests. SNP-heritability was estimated at 0.267 and 0.196 in Europeans and Asians, respectively. We discovered population-specific loci that existed in both European and Asian ethnic groups, as well as the presence of a high concordance of inter-population genetic effects overall. Variants were involved in coordinating eye size (by affecting CC and AL concurrently) whilst maintaining emmetropia (Group A). Meanwhile, other genetic variants were associated with refractive error (Group B); the genetic effect for AL could not compensate the effect for CC, as showing that the pleiotropic effect ratio $\frac{\beta_{AL}}{\beta_{CC}}$ was significant smaller than that of "eye size" variants. A third group of variants was also observed that appeared independent in terms of pleiotropic effects. Besides pathways related to the ECM, the implicated genes were significantly enriched in pathways involved in organism development and growth, eye development, connective tissue cartilage and glycosylation protein activity. Implicated genes with pleiotropic effects on refractive error were involved in diverse pathways related to ECM and organism development and growth.

Our data provide insights into novel genes that regulate CC across European and Asian populations. We found trans-ethnic replication of significant loci, and a high concordance of genetic

effects in variants with little discrepancy in allele frequency between the two ancestry groups. Our results are robust as 90.2% of CC-associated loci were replicated at a genome-wide significance throughout the UK Biobank. We also confirm the association of the MTOR loci 17 with CC in Europeans, in contrast to the lack of replication in previous Europeans studies with much smaller sample size^{11,19}. Although the underlying genetic effects were largely shared between the two ancestry groups, at the same time, population-specific loci were also observed: HDAC11/ FBLN2, ADAMTS19/CHSY3, and FGF9 in Europeans, and RBP3 and CMPK1/STIL previously reported in Asians¹⁸. In these cases, the lead variants were monomorphic in the other non-significant Asian or European populations, respectively, and any signals barely seen from the flanking variants at these loci. Our data show that the trans-ethnic meta-analysis approach yields shared and unique variants for CC in Europeans and Asians.

We used bioinformatics tools to demonstrate the functional connectivity between the associated genes. The newly identified loci such as LMX1B, SOX2, NHSL1, GHSR, HMGA2, IGFBP5, FRAT1, FRAT2, STIL, USP1, HUS1, STON2, and IGF2 are mainly involved in organism growth and eye development. Additional notable CC candidate genes belong to the ADAMTS family, including ADAMTS7, ADAMTS19, and ADAMTS20 involved in organization and function of ECM. Novel genes, such as FBN1, BMP7, COL6A1, THBS4, FBLN2, and KAZALD1, are involved in both ECM formation and organism development. In addition, CC-genes associated with refractive error were involved in basement membrane, endoplasmic reticulum lumen, collagen-containing extracellular matrix, ossification, and osteoblast differentiation, underlying a functional heterogeneity in genes exhibiting pleiotropic effects on both CC and refractive error.

Our study is the most comprehensive study on pleiotropic effects of CC-associated genes on eye size and refractive error in humans. Several small-size studies also have reported the effects of 'eye-size' genes, such as *PDGFRA*^{11,17,19} and *RBP3*¹⁸. Our study confirmed previous findings. Studies in mice and chicken also support the existence of distinctive genetic effects to determine eye sizes, for instance, (1) effects that purely govern eye size, (2) effects restricted to specific ocular dimension (i.e. CC or AL separately), or (3) effects that scale the size of the eye and body simultaneously^{61,62}. Clearly, CC-genes are involved in heterogeneous genetic function.

In human emmetropic eyes, CC is highly correlated with AL, and the two are carefully scaled relative to each other⁶³. Thus, genetic pathways may exist to simultaneously influence AL and CC while maintaining the emmetropic status 12,61,64. In our analyses, we have therefore compared our set of CC loci with their respective associations with AL and refractive error. We identified 'eye-size' genes (HMGA2, RSPO1, HDAC11/FBLN2, RBP3, PDGFRA, NHSL1 and ADAMTS19/CHSY3, and INTS6) that were associated with eye size (e.g. a larger eye with both a flatter CC and longer AL, or vice versa), but not refractive error. The compensatory pleiotropic effect for AL could offset CC's effect toward myopia or hyperopia; namely, a genetic determined 1 mm increase (or decrease) for CC accompanying a 2.92 mm increase (or decrease) on average for AL might cancel out their opposite effects on refractive error. This may represent a carefully coordinated scaling of optical components to maintain the eye in an emmetropic state as it grows. These genetic variants may therefore control variation in eye size independent of refractive error. Among these 'eye-size' genes, HMGA2 and HDAC11/ FBLN2 are likely to have pleiotropic effects on both the coordinated scaling of the eye, as well as height^{65,66}. Similarly, the ADAMTS19 gene encodes metalloproteinases that belong to the ADAMTS family with the members as human growth genes 40 . This is consistent with the findings that height (body size) and eye

size are genetically coordinated ^{12,62}. Among the other 'eye-size' genes identified, some had roles in Wnt signalling (RSPO1 and HDAC11), platelet-derived growth factor signalling (PDGFRA), and extracellular ligands and calcium binding (FBLN2).

In contrast to the group of 'eye-size' genes that do not affect spherical equivalent, there is another group of CC-implicated variants associated with refractive error, with little or no pleiotropic effect on AL (Group B). The pleiotropic ratio $\frac{\beta_{AL}}{\beta_{CC}}$ was significantly smaller than that in 'eye-size' variants, therefore, without adequate compensatory effects on AL, these variants may influence the refractive error status of the eye primarily through CC. There is one exception at loci RP11-91P17.1. Variant rs7000412 T allele was associated with steeper CC (that tends to make the eye more myopic) and shorter AL (less myopic) with overall effects towards to a hyperopic refractive error; thus this variant influenced refractive error likely through AL. Five top loci replicated in UK Biobank for refractive error $(P < 1 \times 10^{-7})$, including CHRND/RPSS56, FBN1, CASC15, RNLS, and KAZALD1, have also been reported in previous CREAM GWAS¹³. Ten loci showed significance in replication after accounting for multiple testing (FDR < 0.01). These genes are actively involved in pathways of basement membrane, endoplasmic reticulum lumen and collagen-containing extracellular matrix, linking to ECM and organism development, growth. Plotnikov et al. recently also proposed a genetic link between CC and refractive error in Europeans⁶⁷. Using CC-associated SNPs in emmetropes as instrument variables, they estimated the causal effect of CC on refractive error to be +1.41 D (95% CI, 0.65–2.16) less myopic refractive error per mm flatter cornea. A significant group of CC-genes identified in our study showing association with spherical equivalent corroborates the finding of an association between CC and refractive error.

The remaining CC loci (Group C) were not significantly associated with refractive error or AL. However, in a majority of these variants, the associations with spherical equivalent, although not statistically significant, were in the expected direction—for instance, a flatter cornea and a more hyperopic spherical equivalent, or vice versa. It is unknown whether these loci may also have modulatory effects on other refractive components of the eye (e.g. lens thickness or anterior chamber depth) that may have attenuated its effect on refractive error. In addition, some of these genes in Group 3 (FNDC3B, COL5A1, COL6A1), together with genes in Group 2 (IGFBP5, FGF9, and CWC27/ADAMT6) was linked to connective tissue disorder (Supplementary Fig. 6) and has been associated with keratoconus^{29,68–71}, a disorder of corneal thinning and steepening, implying a possible effect of CC genes regulating refractive error and keratoconus.

In summary, we have identified 47 genome-wide significant loci for CC (of which 26 are new), through a large-scale tansethnic GWAS meta-analysis. The importance of undertaking this study in individuals of different ethnicities cannot be understated as we identified both population-specific loci in Europeans as well as Asians as well as loci that were common between both ethnicities. These findings provide insights into the underlying genetic aetiology of eye growth and may provide pointers for us to explore why myopia is more prevalent in Asians than Europeans. These CC loci can coordinate AL and eye-size to keep human eyes emmetropic, and some play a role in the development of refractive errors primarily through variations in CC. Implicated genes were significantly enriched in a network linking extracellular matrix organization, developmental process for body and eye and glycosylation protein activities. Elucidating and characterising the heterogeneity of such genes that regulate the optical component dimensions of the eye may enable a better understanding of the biology of both emmetropia and ametropia in humans

Methods

Study populations. The discovery cohorts included 29,580 individuals with European ancestry from 18 studies, and 14,464 with Asian ancestry from 10 studies. General methods, demographics, and phenotyping of the study cohorts have previously been extensively described, and are provided in brief in Supplementary Table 1 and Supplementary Notes. In the replication phase, 88,218 participants of European ancestry from the UK Biobank who had measurements for CC were included in the replication stage, as well as 95,505 participants of European ancestry (from the UK Biobank) with phenotype information for refractive error³. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. All studies were performed with the approval of their local Human Research and Ethics Committee.

Phenotype measurements. All participating CREAM cohorts used similar protocols for the collection of keratometry and other ocular biometric measurements. The protocols have been described in detail elsewhere ^{14,16,59}. In brief, CC radii in the horizontal and vertical meridians were measured using an autokeratometer. The means (in millimetre) of CC from the individuals' two eyes were used for analysis, while the means of the readings from one eye were used when the readings from the other eye were unavailable. Participants were excluded if they had corneal scars, keratoconus, prior refractive or cataract surgery, or other intraocular procedures that could alter CC. For the UK Biobank, participants were excluded from the analyses if they had an eye disorder that may have altered their refractive error or CC (see Supplementary Notes).

Genotyping and imputation. The CREAM study samples were genotyped on either Illumina or Affymetrix platforms. Genotypes were imputed using the 1000 G Genomes Project reference panel (Phase I version 3, March 2012 release). SNPs with low imputation quality were filtered using metrics specific to the imputation method and thresholds used in previous GWAS analyses. The Markov Chain Haplotyping software, IMPUTE^{72,73}, or MACH⁷⁴ were adopted for imputation. A detailed description regarding genotyping platforms and imputation procedures have been outlined (Supplementary Table 2). Stringent quality control of genotype data was applied in each cohort from CREAM. Samples with low call rates (<95%) or with gender discrepancies were excluded. Cryptically related samples and outliers in population structure from principal component analyses were also excluded. SNPs flagged with missingness >5%, gross departure from Hardy-Weinberg equilibrium ($P < 10^{-6}$), and minor allele frequency (MAF) < 1% were removed from further analyses. Poorly imputed markers (IMPUTE info < 0.5 or minimac Rsq < 0.5) were excluded. UK Biobank genotyping arrays were imputed to the HRC reference panel and a combined 1000 Genomes Project -UK10K reference panel using IMPUTE475. Data quality control (QC) was described in the Supplementary

Statistical analyses and meta-analyses. We assumed an additive genetic model where the dosage of each SNP was a continuous variable ranging from 0 to 2 for the effect allele. For each study, an additive allele-dosage regression model, adjusted for both age and sex at each genotyped or imputed SNP, was conducted to determine its association with CC represented as a quantitative trait. An additional adjustment for up to the first five principal components was carried out according to the population substructure in each individual study. For studies that included children and adolescent participants, GWAS analyses were conducted separately by age groups (age ≥ 25 vs. age < 25), as for previous GWAS analyses for corneal astigmatism 76 . Sample outliers with CC values exceeding six standard deviations from the mean were excluded at the study level. The per-SNP meta-analyses were performed in METAL software (https://genome.sph.umich.edu/wiki/METAL) with a weighted inverse-variance approach 78 . A Cochran's Q test was used to assess heterogeneity across studies 78 .

Locus identification and genetic variants annotation. The independent signal from the meta-analysis was determined using LD-clumping procedure in PLINK (https://www.cog-genomics.org/plink2). The index variant was identified ($P < 5 \times 10^{-8}$) in each clump, which was formed for variants with $P < 1 \times 10^{-5}$ that were in LD ($r^2 > 0.1$) and within 500 kb of the index variant. The same variant were assigned to no more than one clump. The LD structure was estimated from the European panel in the 1000 Genome Project as the reference population, or Asian panel for meta-analysis summary statistics in Asians. A locus was identified by an index variant with the regions flanking 250 kb on both sides. For those with multiple signals in one locus (500 kb region) or an overlapping of multiple loci identified from the PLINK clumping procedure, conditional analysis was further performed to confirm the independent signals using GCTA-COJO⁷⁹. The LD structure was estimated in the same manner as for LD-clumping procedure in PLINK. The regional plot was drawn for each identified locus from the combined meta-analysis (Supplementary Fig. 4) using LocusZoom (http://locuszoom.org/).

The coordinates and variant identifiers are reported on the NCBI B37 (hg19) genome build, and annotated using UCSC Genome Browser⁸⁰. We identified variants within each of the LD blocks ($r^2 \ge 0.6$) in European and Asian populations of the 1000 Genomes Project (100 Kb flanking the top SNP at each locus) to apply functional annotations of transcription regulation using HaploReg⁸¹ (https://pubs.broadinstitute.org/mammals/haploreg/haploreg_v3.php) and Encyclopedia of DNA Elements (ENCODE)⁸² data.

Replication in UK Biobank participants. The UK Biobank reported the maximum and minimum corneal power in each eye. After taking the mean of replicate readings, the corneal power in each eye was calculated as the mean of the maximum and minimum values. Corneal power was converted to corneal radius of curvature using the equation CC = (337.5/corneal power). For the genetic analysis of CC in all available participants, we took the average CC of the two eyes as the phenotype. A total of 88,218 individuals were included in the analysis for CC in all available participants. Analyses were performed using BOLT v2.3²². Variant genotype, age, sex, genotyping array (coded as 0 or 1 for the UK BiLEVE or UK Biobank Axiom, respectively) and the first 10 PCs were included as covariates. BOLT uses a mixed model to account for relatedness (kinship) between individuals.

Gene-based tests and pathway analyses. Gene-based testing was conducted using the VEGAS software 25,26 (https://vegas2.qimrberghofer.edu.au/) on the results of separate meta-analyses of GWAS in European and Asian ancestries. Gene-based p-values from different populations were combined by Fisher's method. For samples of European descent, we used the European panel in the 1000 Genome Project as the reference population to estimate patterns of LD. For the Asian ancestry groups, we used the combined 1000 Genome Project Asian samples as the reference population to approximate LD patterns. To include gene regulatory regions, SNPs were included if they fell within 50 kb of the transcription start site of genes.

VEGAS-Pathway analysis 25,26,83 was carried out with pre-specified pathways from Gene Ontology 84 , MSigDB85 (containing canonical pathways and gene-sets from BIOCARTA, REACTOME, KEGG databases), PANTHER86, and pathway commons databases 87 . We filtered these gene-sets to include only pathways with 10–1000 genes, yielding 9734 pathways. Empirical VEGAS-Pathway p values for each pathway were computed by comparing the summed χ^2 test statistics from real data with those generated in 500,000 simulations where the relevant number (according to the size of the pathway) of randomly drawn χ^2 test statistics was summed. To ensure that clusters of genes did not adversely affect results within each pathway, gene-sets were pruned such that each gene was >500 kb away from all other genes in the same pathway. We performed meta-analysis on the two sets of pathway p-values from Asian and European samples by Fisher's method.

We investigated functional annotation of the top identified genes using g: Profiler (https://biit.cs.ut.ee/gprofiler/gost). For g:Profiler, we used "g:GOST" function to perform pathway analysis on identified CC-associated genes. Prespecified pathways include Gene Ontology, pathways from KEGG, Reactome, WikiPathways and protein complexes from CORUM⁸⁸. The significant pathway was claimed at the adjusted *p*-value < 0.05 after correction for multiple testing.

To investigate the connection between the enriched gene-sets, we mapped these gene-sets into network functional enrichment map analysis²⁷. We visualize the network enrichment in Cytoscape software v3.7.1 (https://cytoscape.org/)²⁸. Highly similar gene-sets were placed close together with the interconnectivity among gene-sets drawn by line (edge; similarity coefficient > 0.375).

Association of corneal curvature loci with axial length and spherical equivalent. For all identified CC-associated variants, we assessed their association with refractive error in European participants of UK Biobank (N=95,505). We further assessed the association of CC-associated variants with AL using a subset of CREAM cohorts (N=10,851; Supplementary Table 5). False discovery rates (FDR) from the Benjamini-Hochberg procedure were set at 1% as a threshold of statistical significance²³. We categorized CC variants into three groups: (A) variants were associated with AL, but not spherical equivalent; (B) variants were associated with spherical equivalent; and (C) variants were not associated with spherical equivalent or AL.

Pleiotropic effect ratio $\frac{\beta_{AL}}{\beta_{CC}}$ at each variant was calculated to quantify relevant genetic effects on AL versus effects on CC and the variance was calculated using Delta method. To estimate the pleiotropic effect ratio for variants in each group, we performed meta-analyses in METAL software (https://genome.sph.umich.edu/wiki/METAL) with a weighted inverse-variance approach⁷⁷. A Cochran's Q test was used to assess heterogeneity across variants⁷⁸. Z-statistics were used to test the significant difference of the pleiotropic ratio $\frac{\beta_{AL}}{\beta_{CC}}$.

SNP-heritability estimation. We applied the LD score method²² (https://github.com/bulik/ldsc) using GWAS summary statistics to estimate SNP-h². After merging SNPs with the HapMap3 Asian samples, we had a total of 1,174,487 and 1,085,659 SNPs for the LD score regression analyses for the European and Asian populations, respectively. The LD score matrix was estimated from the 1000 Genomes Project Asian reference panel, or European reference panel separately,

with a 1 cM sliding window. We calculated the heritability using the software Idsc v1.0.0. The resulting regression slope was multiplied by the number of effective SNPs in the reference panel from the 1000 Genomes Project data²².

Gene expression in human ocular tissues. To assess gene expression in human tissues, we examined the Ocular Tissue Database (OTDB) (https://genome.uiowa.edu/otdb/) and the EyeSAGE database^{89,90} (http://people.duke.edu/~bowes007/EyeSAGE.htm). The estimated gene and exome level abundances are available online. Normalization of gene expression used the PLIER method with GC-background correction⁸⁹. Relationships between genotype and *cis* regulation of gene expression levels were assessed using expression quantitative trait locus (eQTL) associations obtained from GTEx Portal database⁹¹ (https://gtexportal.org/home/).

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The summary statistics of the meta-analysis combining studies in CREAM are included in Supplementary Data 8. To protect the privacy of the participants in our cohorts, the datasets generated during and/or analysed during the current study are available from the corresponding authors on reasonable request.

Received: 22 August 2019; Accepted: 24 January 2020; Published online: 19 March 2020

References

- Dandona, L. & Dandona, R. What is the global burden of visual impairment? BMC Med. 4, 6–6 (2006).
- Holden, B. A. et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123, 1036–1042 (2016).
- Flaxman, S. R. et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob. Health* 5, e1221–e1234 (2017).
- Atchison, D.A. & George, S. Optics of the human eye, 288–288 (Butterworth-Heinemann, 2000).
- Ip, J. M. et al. Ethnic differences in refraction and ocular biometry in a population-based sample of 11–15-year-old Australian children. Eye 22, 649–656 (2008).
- Kleinstein, R. N. et al. Refractive error and ethnicity in children. Arch. Ophthalmol. 121, 1141–1141 (2003).
- Lim, L. S. et al. Distribution and determinants of ocular biometric parameters in an Asian population: the Singapore Malay eye study. *Invest Ophthalmol.* Vis. Sci. 51, 103–109 (2010).
- Lyhne, N., Sjolie, A. K., Kyvik, K. O. & Green, A. The importance of genes and environment for ocular refraction and its determiners: a population based study among 20-45 year old twins. Br. J. Ophthalmol. 85, 1470–1476 (2001).
- Cagigrigoriu, A., Gregori, D., Cortassa, F., Catena, F. & Marra, A. Heritability of corneal curvature and astigmatism: a videokeratographic child-parent comparison study. *Cornea* 26, 907–912 (2007).
- Klein, A. P. et al. Heritability analysis of spherical equivalent, axial length, corneal curvature, and anterior chamber depth in the Beaver Dam Eye Study. Arch. Ophthalmol. 127, 649–655 (2009).
- Guggenheim, J. A. et al. A genome-wide association study for corneal curvature identifies the platelet-derived growth factor receptor alpha gene as a quantitative trait locus for eye size in white Europeans. *Molecular Vision* 19, 243–253 (2013).
- Guggenheim, J. A. et al. Coordinated genetic scaling of the human eye: shared determination of axial eye length and corneal curvature. *Investigative* Ophthalmol. Vis. Sci. 54, 1715–1721 (2013).
- Tedja, M. S. et al. Genome-wide association meta-analysis highlights lightinduced signaling as a driver for refractive error. Nat. Genet 50, 834–848 (2018).
- Verhoeven, V. J. M. et al. Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat. Genet. 45, 314–318 (2013).
- Kiefer, A. K. et al. Genome-wide analysis points to roles for extracellular matrix remodeling, the visual cycle, and neuronal development in myopia. PLoS Genet. 9, e1003299–e1003299 (2013).
- Cheng, C. Y. et al. Nine loci for ocular axial length identified through genomewide association studies, including shared loci with refractive error. Am. J. Hum. Genet 93, 264–277 (2013).
- Han, S. et al. Association of variants in FRAP1 and PDGFRA with corneal curvature in Asian populations from Singapore. *Hum. Mol. Genet* 20, 3693–3698 (2011).

- 18. Chen, P. et al. CMPK1 and RBP3 are associated with corneal curvature in Asian populations. *Hum. Mol. Genet.* 23, 6129–6136 (2014).
- Mishra, A. et al. Genetic variants near PDGFRA are associated with corneal curvature in Australians. *Investigative Ophthalmol. Vis. Sci.* 53, 7131–7136 (2012).
- The UK Biobank Eye and Vision Consortium. Is a large eye size a risk factor for myopia? A Mendelian randomization study. bioRxiv, 240283 (2017).
- Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet* 47, 291–295 (2015).
- Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet 47, 1236–1241 (2015).
- Benjamini, Y. & Yosef, H. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 12 (1995).
- Miyake, M. et al. Identification of myopia-associated WNT7B polymorphisms provides insights into the mechanism underlying the development of myopia. Nat. Commun. 6, 6689 (2015).
- Liu, J. Z. et al. A versatile gene-based test for genome-wide association studies. Am. J. Hum. Genet. 87, 139–145 (2010).
- Mishra, A. & Macgregor, S. VEGAS2: software for more flexible gene-based testing. Twin Res. Hum. Genet. 18, 86–91 (2015).
- Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. *PLoS ONE* 5, e13984 (2010).
- Cline, M. S. et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2, 2366–2382 (2007).
- Lu, Y. et al. Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus. *Nat. Genet* 45, 155–163 (2013).
- Pressman, C. L., Chen, H. & Johnson, R. L. lmx1b, a LIM homeodomain class transcription factor, is necessary for normal development of multiple tissues in the anterior segment of the murine eve. *Genesis* 26, 15–25 (2000).
- Chen, H. et al. Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nat. Genet 19, 51–55 (1998).
- Choquet, H. et al. A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. Nat. Commun. 9, 2278 (2018).
- Gharahkhani, P. et al. Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma. Sci. Rep. 8, 3124 (2018).
- Shiga, Y. et al. Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. *Hum. Mol. Genet* 27, 1486–1496 (2018).
- Schneider, A., Bardakjian, T., Reis, L. M., Tyler, R. C. & Semina, E. V. Novel SOX2 mutations and genotype-phenotype correlation in anophthalmia and microphthalmia. Am. J. Med. Genet. Part A 149A, 2706–2715 (2009).
- Cao, Y., Mitchell, E. B., Gorski, J. L., Hollinger, C. & Hoppman, N. L. Two cases with de novo 3q26.31 microdeletion suggest a role for FNDC3B in human craniofacial development. Am. J. Med. Genet A 170, 3276–3281 (2016).
- Soranzo, N. et al. Meta-analysis of genome-wide scans for human adult stature identifies novel loci and associations with measures of skeletal frame size. PLoS Genet. 5, e1000445-e1000445 (2009).
- Kelwick, R., Desanlis, I., Wheeler, G. N. & Edwards, D. R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 16, 113–113 (2015).
- Cain, S. A., Mularczyk, E. J., Singh, M., Massam-Wu, T. & Kielty, C. M. ADAMTS-10 and -6 differentially regulate cell-cell junctions and focal adhesions. Sci. Rep. 6, 35956–35956 (2016).
- Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. Nature 542, 186–190 (2017).
- Argraves, W. S., Dickerson, K., Burgess, W. H. & Ruoslahti, E. Fibulin, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 58, 623–629 (1989).
- Kanai, A. [The pathogenesis and treatment of corneal disorders]. Nippon Ganka Gakkai zasshi 106, 757–776; (2002).
- Kabza, M. et al. Collagen synthesis disruption and downregulation of core elements of TGF-β, Hippo, and Wnt pathways in keratoconus corneas. Eur. J. Hum. Genet. 25, 582–590 (2017).
- 44. Waite, K. A. & Eng, C. From developmental disorder to heritable cancer: it's all in the BMP/TGF- β family. *Nat. Rev. Genet.* **4**, 763–773 (2003).
- Dudley, A. T., Lyons, K. M. & Robertson, E. J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev. 9, 2795–2807 (1995).
- Zouvelou, V. et al. Generation and functional characterization of mice with a conditional BMP7 allele. Int. J. Developmental Biol. 53, 597–603 (2009).
- Martinez-Morales, J. R. et al. ojoplano-mediated basal constriction is essential for optic cup morphogenesis. *Development* 136, 2165–2175 (2009).
- Marshall, G. E., Konstas, A. G. & Lee, W. R. Immunogold fine structural localization of extracellular matrix components in aged human cornea II. Collagen types V and VI. Graefe's Arch. Clin. Exp. Ophthalmol. 229, 164–171 (1991).

- Choquet, H. et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. Nat. Commun. 8, 2108 (2017).
- Schwarze, U., Atkinson, M., Hoffman, G. G., Greenspan, D. S. & Byers, P. H. Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II). Am. J. Hum. Genet. 66, 1757–1765 (2000).
- Villani, E. et al. The cornea in classic type Ehlers-Danlos syndrome: macroand microstructural changes. *Invest. Opthalmol. Vis. Sci.* 54, 8062–8062 (2013).
- Iglesias, A. I. et al. Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases. *Nat. Commun.* 9, 1864 (2018).
- Vitart, V. et al. New loci associated with central cornea thickness include COL5A1, AKAP13 and AVGR8. Hum. Mol. Genet. 19, 4304–4311 (2010).
- Lawler, J., McHenry, K., Duquette, M. & Derick, L. Characterization of human thrombospondin-4. J. Biol. Chem. 270, 2809–2814 (1995).
- Zhao, S. et al. Patterning the optic neuroepithelium by FGF signaling and Ras activation. *Dev. (Camb., Engl.)* 128, 5051–5060 (2001).
- 56. Clevers, H. Wnt/ β -catenin signaling in development and disease. *Cell* 127, 469–480 (2006).
- Jin, E.-J., Burrus, L. W. & Erickson, C. A. The expression patterns of Wnts and their antagonists during avian eye development. *Mech. Dev.* 116, 173–176 (2002).
- Fokina, V. M. & Frolova, E. I. Expression patterns of Wnt genes during development of an anterior part of the chicken eye. *Dev. Dyn.* 235, 496–505 (2006).
- Van Raay, T. J. & Vetter, M. L. Wnt/frizzled signaling during vertebrate retinal development. *Dev. Neurosci.* 26, 352–358 (2004).
- Meyers, J. R. et al. β-catenin/Wnt signaling controls progenitor fate in the developing and regenerating zebrafish retina. Neural Dev. 7, 30–30 (2012).
- 61. Wang, L. et al. Heritability of ocular component dimensions in mice phenotyped using depth-enhanced swept source optical coherence tomography. *Exp. Eye Res.* **93**, 482–490 (2011).
- Prashar, A. et al. Common determinants of body size and eye size in chickens from an advanced intercross line. Exp. Eye Res 89, 42–48 (2009).
- 63. Sorsby, A., Leary, G. A. & Richards, M. J. Correlation ametropia and component ametropia. Vis. Res. 2, 309–313 (1962).
- Chen, Y. P. et al. Heritability of ocular component dimensions in chickens: genetic variants controlling susceptibility to experimentally induced myopia and pretreatment eye size are distinct. *Invest. Ophthalmol. Vis. Sci.* 52, 4012–4020 (2011).
- Weedon, M. N. et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. *Nat. Genet.* 39, 1245–1250 (2007)
- Lango Allen, H. et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467, 832–838 (2010).
- Plotnikov D. & Guggenheim J. UK Biobank Eye and Vision Consortium. Is a large eye size a risk factor for myopia? A Mendelian randomization study. bioRxiv: https://doi.org/10.1101/240283v1.full (2017).
- Ha, N. T., Nakayasu, K., Murakami, A., Ishidoh, K. & Kanai, A. Microarray analysis identified differentially expressed genes in keratocytes from keratoconus patients. *Curr. Eye Res.* 28, 373–379 (2004).
- Li, X. et al. Genetic association of COL5A1 variants in keratoconus patients suggests a complex connection between corneal thinning and keratoconus. *Invest. Ophthalmol. Vis. Sci.* 54, 2696–2704 (2013).
- Khaled, M. L. et al. Differential expression of coding and long noncoding RNAs in keratoconus-affected corneas. *Invest. Ophthalmol. Vis. Sci.* 59, 2717–2728 (2018).
- Bykhovskaya, Y., Gromova, A., Makarenkova, H.P., Rabinowitz, Y.S.
 Abnormal regulation of extracellular matrix and adhesion molecules in corneas of patients with keratoconus. *Int J Keratoconus Ectatic Corneal Dis.* 5, 63–70 (2016).
- Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* 39, 906–913 (2007).
- Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
- Li, Y., Willer, C. J., Ding, J., Scheet, P. & Abecasis, G. R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* 34, 816–834 (2010).
- Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018).
- Li, Q. et al. Genome-wide association study for refractive astigmatism reveals genetic co-determination with spherical equivalent refractive error: the CREAM consortium. *Hum Genet.* 134, 131–146 (2015).
- Stephens, M. & Balding, D. J. Bayesian statistical methods for genetic association studies. Nat. Rev. Genet. 10, 681–690 (2009).

- Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).
- Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* 44, 369–375 (2012). S1-3.
- Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
- Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* 40, D930–D934 (2012).
- Consortium, E. P. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
- Mishra, A. & MacGregor, S. A novel approach for pathway analysis of GWAS data highlights role of BMP signaling and muscle cell differentiation in colorectal cancer susceptibility – Erratum. Twin Res. Hum. Genet. 20, 186–186 (2017).
- Gene Ontology Consortium, T.G.O. The Gene Ontology project in 2008. Nucleic Acids Res. 36, D440–D444 (2008).
- Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
- Thomas, P. D. et al. PANTHER: a library of protein families and subfamilies indexed by function. *Genome Res.* 13, 2129–2141 (2003).
- 87. Cerami, E. G. et al. Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Res.* **39**, D685–D690 (2011).
- 88. Reimand, J. et al. g:Profiler-a web server for functional interpretation of gene lists (2016 update). *Nucleic Acids Res.* **44**, W83–W89 (2016).
- Wagner, A. H. et al. Exon-level expression profiling of ocular tissues. Exp. Eye Res. 111, 105–111 (2013).
- Bowes Rickman, C. et al. Defining the human macula transcriptome and candidate retinal disease genes using EyeSAGE. *Invest. Ophthalmol. Vis. Sci.* 47, 2305–2316 (2006).
- 91. Rivas, M. A. et al. Human genomics. Effect of predicted protein-truncating genetic variants on the human transcriptome. *Science* **348**, 666–669 (2015).

Acknowledgements

We gratefully thank all the participants, volunteers, and staffs who participated and contributed to the studies. We thank the members of the cited consortiums for making their data available. A full list of funding information and acknowledgements by individual study can be found in the Supplementary Note.

Author contributions

Q.F., S.-M.S., P.N.B., and C.-Y.C. conceived the project. Q.F., A.P., X.G., V.J.M.V., V.V., J.A.G., M.M., J.W.L.T., A.P.K., L.Z., S.M., R.H., P.C., G.B., J.W., S.E.S., M.S.T., A.W.H., and J.X. performed analyses. C.L., N.Y.Q.T., Y.X.W., S.S., J.M., A.M., N.G.M., S.Y., C.E.P., M.Y., A.E.G.H., C.A.E., J.P., V.W.V.J., C.M.Van D., C.H., O.P., E.-S.T., H.Y., P.G.H., T.L. Y., A. T., J.J.W., P.M., N.P., O.P., P.J.F., M.F., S.P.Y., C.W., C.J.H., J.B.J., M.H., D.A.M., T.-Y.W., C.C.W.K., S.-M.S., and C.-Y.C. were responsible for collecting clinic data and performing genotyping in each study. Q.F., N.Y.Q.T., S.-M.S., C.-Y.C., and P.N.B. drafted the paper. J.A.G., V.J.M.V., M.S.T., and D.A.M. critically reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s42003-020-0802-y.

Correspondence and requests for materials should be addressed to Q.F. or C.-Y.C.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020

Qiao Fan^{1,2,114,23}, Alfred Pozarickij^{3,114}, Nicholas Y.Q. Tan^{4,114}, Xiaobo Guo^{5,6,114}, Virginie J.M. Verhoeven ^{7,8,114}, Veronique Vitart ⁹, Jeremy A. Guggenheim ³, Masahiro Miyake¹⁰, J. Willem L. Tideman^{7,11}, Anthony P. Khawaja ^{12,13}, Liang Zhang ¹⁴, Stuart MacGregor ¹⁵, René Höhn^{16,17}, Peng Chen¹⁸, Ginevra Biino¹⁹, Juho Wedenoja ^{20,21}, Seyed Ehsan Saffari ¹, Milly S. Tedja ^{7,11}, Jing Xie^{22,23}, Carla Lanca ²⁴, Ya Xing Wang ²⁵, Srujana Sahebjada^{23,26}, Johanna Mazur²⁷, Alireza Mirshahi^{16,28}, Nicholas G. Martin ¹⁵, Seyhan Yazar²⁹, Craig E. Pennell³⁰, Maurice Yap ³¹, Annechien E.G. Haarman^{7,11}, Clair A. Enthoven^{7,11}, JanRoelof Polling^{7,11,32}, Consortium for Refractive Error and Myopia (CREAM)*, UK Biobank Eye and Vision Consortium*, Alex W. Hewitt ^{29,33}, Vincent W.V. Jaddoe ³⁴, Cornelia M. van Duijn¹¹, Caroline Hayward ⁹, Ozren Polasek³⁵, E-Shyong Tai¹⁸, Hosoda Yoshikatsu¹⁰, Pirro G. Hysi ³⁶, Terri L. Young ³⁷, Akitaka Tsujikawa¹⁰, Jie Jing Wang ^{38,39}, Paul Mitchell³⁹, Norbert Pfeiffer ¹⁶, Olavi Pärssinen^{40,41}, Paul J. Foster ¹², Maurizio Fossarello^{42,43}, Shea Ping Yip⁴⁴, Cathy Williams⁴⁵, Christopher J. Hammond ³⁶, Jost B. Jonas ^{25,46}, Mingguang He^{47,48}, David A. Mackey^{29,33}, Tien-Yin Wong^{2,4,38}, Caroline C.W. Klaver ^{7,11,49}, Seang-Mei Saw^{2,18,24,115}, Paul N. Baird ^{26,115} & Ching-Yu Cheng^{2,14,115}

¹Centre for Quantitative Medicine, Duke-NUS Medical School, 20 College Road, 169856 Singapore, Singapore. ²Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore. ³School of Optometry and Vision Sciences, Cardiff

University, Cardiff CF24 4HQ, UK. ⁴Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore. ⁵Department of Statistical Science, School of Mathematics, Sun Yat-Sen University, Guangzhou, China. 6Southern China Center for Statistical Science, Sun Yat-Sen University, Guangzhou, China. ⁷Department of Ophthalmology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. ⁸Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands. ⁹Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK. ¹⁰Department of Ophthalmology and Visual Sciences, Kyoto University, Kyoto 6068507, Japan. 11Department of Epidemiology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. 12NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK. 13 Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK. 14 Ocular Epidemiology Research Group, Singapore Eye Research Institute, Singapore, Singapore. ¹⁵QIMR Berghofer Medical Research Institute, Brisbane, Australia. 16 Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany. ¹⁷Department of Ophthalmology, Inselspital, University Hospital Bern, University of Bern, Bern 3010, Switzerland. ¹⁸Saw Swee Hock School of Public Health, National University Health Systems, National University of Singapore, Singapore, Singapore. 19 Institute of Molecular Genetics, National Research Council of Italy, Pavia 27100, Italy. 20 Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki FI-00290, Finland. ²¹Department of Public Health, University of Helsinki, Helsinki FI-00290, Finland. ²²Occupational and Environmental Health Sciences, School of Public Health and Preventative Medicine, Monash University, Melbourne 3004, Australia. ²³Centre for Eye Research Australia (CERA), University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne 3002, Australia. ²⁴Myopia Research Group, Singapore Eye Research Institute, Singapore, Singapore. ²⁵Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. ²⁶Department of Surgery, Ophthalmology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne 3002, Australia. ²⁷Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany. ²⁸Dardenne Eye Hospital, Bonn-Bad Godesberg, Godesberg 53117, Germany. ²⁹Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute, Perth, Australia. ³⁰School of Women's and Infants' Health, The University of Western Australia, Perth, WA 6009, Australia. 31School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China. 32 Orthoptics & Optometry, University of Applied Sciences, Utrecht, Netherlands. 33 Menzies Institute for Medical Research, School of Medicine, University of Tasmania, Hobart, Australia. 34Generation R Study Group, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. 35 Faculty of Medicine, University of Split, Croatia, Split 21000, Croatia. 36 Section of Academic Ophthalmology, School of Life Course Sciences, King's College London, London, UK. ³⁷Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA. ³⁸Duke-NUS Medical School, Singapore, Singap Health Sciences, University of Jyväskylä, Jyväskylä FI-40100, Finland. 41 Department of Ophthalmology, Central Hospital of Central Finland, Jyväskylä FI-40100, Finland. ⁴²San Giovanni di Dio hospital, Clinica Oculistica, Azienda Ospedaliera Universitaria di Cagliari, Cagliari 09131, Italy. ⁴³Department of Surgical Sciences, Eye Clinic, University of Cagliari, Cagliari 09131, Italy. ⁴⁴Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China. ⁴⁵Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 1NU, UK. ⁴⁶Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ⁴⁷State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China. ⁴⁸Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, VIC, Australia. ⁴⁹Department Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands. 114These authors contributed equally: Qiao Fan, Alfred Pozarickij, Nicholas Y.Q. Tan, Xiaobo Guo, Virginie J.M. Verhoeven. 115These authors jointly supervised this work: Seang-Mei Saw, Paul N. Baird, Ching-Yu Cheng. *Lists of authors and their affiliations appear at the end of the paper.

□ email: giao.fan@duke-nus.edu.sg; cheng.ching.yu@seri.com.sg

Consortium for Refractive Error and Myopia (CREAM)

Joan E. Bailey-Wilson⁵⁰, Amutha Barathi Veluchamy^{4,51,52}, Kathryn P. Burdon⁵³, Harry Campbell⁵⁴, Li Jia Chen⁵⁵, Emily Y. Chew⁵⁶, Jamie E. Craig⁵⁷, Phillippa M. Cumberland⁵⁸, Margaret M. Deangelis⁵⁹, Cécile Delcourt⁶⁰, Xiaohu Ding⁴⁷, David M. Evans^{61,62,63}, Puya Gharahkhani⁶⁴, Adriana I. Iglesias^{65,66,67}, Toomas Haller⁶⁸, Xikun Han⁶⁴, Quan Hoang^{4,69}, Robert P. Igo Jr.⁷⁰, Sudha K. Iyengar^{70,71,72}, Mika Kähönen^{73,74}, Jaakko Kaprio^{75,76}, Barbara E. Klein⁷⁷, Ronald Klein⁷⁷, Jonathan H. Lass^{70,71}, Kris Lee⁷⁷, Terho Lehtimäki^{78,79}, Deyana D. Lewis⁵⁰, Qing Li⁸⁰, Shi-Ming Li⁸¹, Leo-Pekka Lyytikäinen^{78,79}, Akira Meguro⁸², Andres Metspalu⁶⁸, Candace D. Middlebrooks⁵⁰, Nobuhisa Mizuki⁸², Anthony M. Musolf⁵⁰, Stefan Nickels⁸³, Konrad Oexle⁸⁴, Chi Pui Pang⁵⁵, Andrew D. Paterson⁸⁵, Jugnoo S. Rahi^{58,86,87}, Olli Raitakari^{88,89}, Igor Rudan⁵⁴, Dwight Stambolian⁹⁰, Claire L. Simpson^{50,91}, Ningli Wang⁸¹, Wen Bin Wei⁹², Katie M. Williams³⁶, James F. Wilson^{54,93}, Robert Wojciechowski^{50,94,95}, Kenji Yamashiro⁹⁶, Jason C.S. Yam⁵⁵ & Xiangtian Zhou⁹⁷

⁵⁰Computational and Statistical Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. ⁵¹Duke-NUS Medical School, Singapore, Sing

Queensland Diamantina Institute, Brisbane, Queensland, Australia. 62MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. Department of Population Health Sciences, Bristol Medical School, Bristol, UK. 64Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ⁶⁵University of Leeds, Leeds, UK. ⁶⁶NIHR Biomedical Research Centre, London, UK. ⁶⁷University of Southampton, Southampton, UK. ⁶⁸Cardiff University, Cardiff, UK. ⁶⁹Department of Ophthalmology, Columbia University, New York, USA. ⁷⁰Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA. 71Department of Ophthalmology and Visual Sciences, Case Western Reserve University and University Hospitals Eye Institute, Cleveland, Ohio, USA. 72 Department of Genetics, Case Western Reserve University, Cleveland, Ohio, USA. 73 Department of Clinical Physiology, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, Finland. ⁷⁴Finnish Cardiovascular Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. ⁷⁵Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK. ⁷⁶Institute for Molecular Medicine Finland FIMM, HiLIFE Unit. University of Helsinki, Helsinki, Finland. 77 Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison. Madison, Wisconsin, USA. ⁷⁸Department of Clinical Chemistry, Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. ⁷⁹Department of Clinical Chemistry, Fimlab Laboratories, University of Tampere, Tampere, Finland. ⁸⁰National Human Genome Research Institute, National Institutes of Health, Baltimore, USA. ⁸¹Nottingham University Hospitals NHS Trust, Nottingham, UK. 82 Department of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan. ⁸³Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. ⁸⁴Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany. ⁸⁵Program in Genetics and Genome Biology, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada. 86NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. 87Ulverscroft Vision Research Group, University College London, London, UK. 88Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland. ⁸⁹Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland. ⁹⁰Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USA, 91 Department of Genetics, Genomics and Informatics, University of Tennessee Health Sciences Center, Memphis, Tenessee, USA. 92Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing, China. 93 MRC Human Genetics Unit, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK. ⁹⁴Department of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. ⁹⁵Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 96 Department of Ophthalmology, Otsu Red Cross Hospital, Nagara, Japan. 97 School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.

UK Biobank Eye and Vision Consortium

Tariq Aslam⁹⁸, Sarah A. Barman⁹⁹, Jenny H. Barrett⁶⁵, Paul Bishop⁹⁸, Peter Blows⁶⁶, Catey Bunce¹⁰⁰, Roxana O. Carare⁶⁷, Usha Chakravarthy¹⁰¹, Michelle Chan⁶⁶, Sharon Y.L. Chua⁶⁶, David P. Crabb¹⁰², Philippa M. Cumberland¹⁰², Alexander Day⁶⁶, Parul Desai⁶⁶, Bal Dhillon¹⁰³, Andrew D. Dick¹⁰⁴, Cathy Egan⁶⁶, Sarah Ennis⁶⁷, Marcus Fruttiger⁶⁶, John E.J. Gallacher¹⁰⁵, David F. Garway-Heath⁶⁶, Jane Gibson⁶⁷, Dan Gore⁶⁶, Alison Hardcastle⁶⁶, Simon P. Harding¹⁰⁶, Ruth E. Hogg¹⁰¹, Pearse A. Keane⁶⁶, Sir Peng T. Khaw⁶⁶, Gerassimos Lascaratos⁶⁶, Andrew J. Lotery⁶⁷, Tom Macgillivray¹⁰³, Sarah Mackie⁶⁵, Keith Martin¹⁰⁷, Michelle McGaughey¹⁰¹, Bernadette McGuinness¹⁰¹, Gareth J. McKay¹⁰¹, Martin McKibbin¹⁰⁸, Danny Mitry⁶⁶, Tony Moore⁶⁶, James E. Morgan⁶⁸, Zaynah A. Muthy⁶⁶, Eoin O'Sullivan¹⁰⁹, Chris G. Owen¹¹⁰, Praveen Patel⁶⁶, Euan Paterson¹⁰¹, Tunde Peto¹⁰¹, Axel Petzold¹⁰², Jugnoo S. Rahi¹⁰², Alicja R. Rudnikca¹¹⁰, Jay Self⁶⁷, Sobha Sivaprasad⁶⁶, David Steel¹¹¹, Irene Stratton⁷⁵, Nicholas Strouthidis⁶⁶, Cathie Sudlow¹⁰³, Dhanes Thomas⁶⁶, Emanuele Trucco¹¹², Adnan Tufail⁶⁶, Stephen A. Vernon⁸¹, Ananth C. Viswanathan⁵⁶, Katie Williams⁶⁷, Jayne V. Woodside¹⁰¹, Max M. Yates¹¹³, Jennifer Yip¹⁰⁷ & Yalin Zheng¹⁰⁶

⁹⁸University of Manchester, Manchester, England. ⁹⁹Kingston University, London, USA. ¹⁰⁰King's College London, London, USA. ¹⁰¹Queens University Belfast, UK. ¹⁰²University College London, London, USA. ¹⁰³University of Edinburgh, Edinburgh, UK. ¹⁰⁴University of Bristol, Belfast, UK. ¹⁰⁵University of Oxford, Oxford, USA. ¹⁰⁶University of Liverpool, Liverpool, UK. ¹⁰⁷University of Cambridge, Cambridge, USA. ¹⁰⁸Leeds Teaching Hospitals NHS Trust, Leeds, UK. ¹⁰⁹King's College Hospital NHS Foundation Trust, London, UK. ¹¹⁰University of London, London, UK. ¹¹¹Newcastle University, Newcastle, UK. ¹¹²University of Dundee, Dundee, UK. ¹¹³University of East Anglia, Anglia, UK.